Document:

EXHIBIT 10.5

                        SIMON PELMAN CONSULTING AGREEMENT
                              CONSULTING AGREEMENT

This Agreement is made on December 28, 2001 between International Wireless, Inc.
(the  "Company")  and  Simon  Pelman  (the  "Consultant"),  and  is effective on
December  28, 2001 and supersedes all prior consulting agreements, including the
Consulting  Agreement  Dated  December  27,  2001 between the same parties.  The
Consultant  has  extensive  experience  regarding  operating  a  large  business
enterprise  and  in  particular with doing business with state agencies, and the
Company  seeks  to  benefit  from  the  Consultant's  expertise by retaining the
Consultant  as  its  Consultant  in  dealing with state agencies. The Consultant
wishes  to perform consulting services for the Company. Accordingly, the Company
and  the  Consultant  agree  as  follows:

9.   Services

     a.   The  consultant  shall  provide  advice and consulting services to the
          Company  with  respect to matters related to doing business with state
          agencies.  The  Consultant  shall  be  engaged  by  the  Company  as a
          consultant  for the exchange of ideas only and under the terms of this
          Agreement, shall not directly conduct business for or on behalf of the
          Company.

     b.   Upon request by the Company and in return for compensation detailed in
          Article  2,  the  Consultant shall keep the Company informed about the
          availability  of  state  contracts in regard to wireless technology as
          they  may  be  available  from  time  to  time.

10.  Compensation

     As  full  consideration  for  the  consulting  services  provided  by  the
     Consultant,  the  Company  shall  pay  to  the  Consultant  with options to
     purchase  140,000 (One Hundred Forty) common shares of the company at $0.46
     USD  per  share.  It  is  fully  understood  by the parties herein that the
     Company  has  not  registered  said  options  as of this date, but that the
     Company  plans  to  file  a  Form  S-8 to register the Company Stock Option
     Agreement  which will include these options, as soon as practical after its
     audit  for  the  merger  with Origin Investment Inc. is completed and filed
     with  the  Securities  and  Exchange  Commission.

19.  Confidentiality

     a.   Either  party may disclose to the other party any information that the
          disclosing  party  would normally freely disclose to the other members
          of  the  wireless  community  at  large,  whether  by  publication, by
          presentation  at  seminars,  or  in  informal  industry  discussions.

<PAGE>
     b.   The  parties  may  wish,  from  time  to time, in connection with work
          contemplated  under  this  Agreement,  to  disclose  confidential
          information  to  each  other  ("Confidential Information"). Each party
          will  use  reasonable  efforts to prevent the disclosure of any of the
          other  party's  Confidential Information to third parties for a period
          of  one  (1)  year  from  receipt  thereof.  The recipient may acquire
          information  that  pertains  to  the discloser's processes, equipment,
          programs,  developments,  or  plans that is both (i) disclosed or made
          known  by  the  disclosure  to  the  recipient  and (ii) identified in
          writing  as  "proprietary" by the disclosure. The recipient agrees not
          to  disclose  any  Confidential Information to third parties or to use
          any Confidential Information for any purpose other than performance of
          the  services  contemplated  by  this Agreement, without prior written
          consent  of  the  Company.

     c.   Confidential  Information  subject  to paragraph 3(b) does not include
          information  that  (i)  is  or  later  becomes available to the public
          through no breach of this Agreement by the recipient; (ii) is obtained
          by  the  recipient  from  a  third  party  who  had the legal right to
          disclose  the  information  to  the recipient; (iii) is already in the
          possession  of  the  recipient  on  the  date  this  Agreement becomes
          effective;  (iv)  is  independently  developed by recipient; or (v) is
          required  to  be  disclosed  by  law,  government regulation, or court
          order.

20.  Return  of  Materials

     The Consultant agrees to promptly return, following the termination of this
     Agreement  or  upon earlier request by the Company, all drawings, tracings,
     and  written  materials  in  the  Consultant's  possession  supplied by the
     Company in conjunction with the Consultant's consulting services under this
     Agreement.

21.  Term  and  Termination

     This Agreement shall be for a term of six months, renewable upon reasonable
     terms  and  conditions  as  may  be  agreed  upon  by  the  Company and the
     Consultant.

22.  Miscellaneous

     a.   This  Agreement  shall inure to the benefit of and be binding upon the
          respective  heirs, executors, successors, representatives, and assigns
          of  the  parties,  as  the  case  may  be.

     b.   The  relationship  created  by  this  Agreement  shall  be  that  of
          independent  contractor, and the Consultant shall have no authority to
          bind or act as agent for the Company or its employees for any purpose.

     c.   The  Company  will  not  use  the  Consultant's name in any commercial
          advertisement  or  similar  material used to promote or sell products,
          unless  the  Company  obtains  in  advance  the written consent of the
          Consultant.

<PAGE>
     d.   Notice  given  by one party to the other hereunder shall be in writing
          and  deemed  to  have been properly given if deposited with the United
          States  Postal  Service,  registered  or  certified mail, addressed as
          follows:

                         International  Wireless,  Inc.
                         120  Presidential  Way
                         Woburn,  Massachusetts  01801

                         Mr.  Simon  Pelman
                         Union  Plaza
                         33-23  Union  Street
                         Flushing,  New  York  11354

     e.   This  Agreement  replaces  all previous agreements and the discussions
          relating  to  the  subject  matters  hereof and constitutes the entire
          agreement  between  the Company and the Consultant with respect to the
          subject  matters of this Agreement. This Agreement may not be modified
          in  any  respect by any verbal statement, representation, or agreement
          made by any employee, officer, or representative of the Company, or by
          any written documents unless it is signed by an officer of the Company
          and  by  the  Consultant.

     f.   If any term or provision of this Agreement is deemed invalid, contrary
          to,  or  prohibited  under  applicable  laws  or  regulation  of  any
          jurisdiction,  this  Agreement  (save  only  this  sentence)  shall be
          invalid.

IN  WITNESS WHEREOF, the parties have executed this Agreement effective the date
first  stated  above.

By: /s/ Stanley  A.  Young
    ------------------------------
    Stanley  A.  Young,  President
    International  Wireless,  Inc.

By: /s/  Simon  Pelman
    ------------------------------
    Simon  Pelman,  Consultant

<PAGE>EXHIBIT 10.6

                   SIMON PELMAN CONSULTING AGREEMENT AMENDMENT
                         CONSULTING AGREEMENT AMENDMENT

This  Agreement,  dated  this  the  17th  day  of  April 2002, hereby amends the
                                    ----           ----------
Consulting  Agreement  (the  "Consulting  Agreement")  made on December 28, 2001
between  International  Wireless,  Inc.  (the  "Company")  and Simon Pelman (the
"Consultant"),  and  amends  or  supersedes,  all  prior  consulting agreements,
including  the  Consulting  Agreement  dated  December 27, 2001 between the same
parties.

Accordingly,  the  Company  and  the Consultant agree to amend Section 2, titled
Compensation,  of  the  Consulting  Agreement  to  read  as  follows:

11.  Compensation

     As  full  consideration  for  the  consulting  services  provided  by  the
     Consultant,  the  Company  shall  pay  to  the  Consultant  with options to
     purchase  150,000 (One Hundred Fifty Thousand) common shares of the company
     at  USD$0.46 per share. These options shall expire on December 28, 2006. It
     is  fully  understood  by  the  parties  herein  that  the  Company has not
     registered said options as of this date, but that the Company plans to file
     a  Form  S-8  to  register  the  Company  Stock Option Agreement which will
     include  these options, as soon as practical after its audit for the merger
     with  Origin Investment Inc. is completed and filed with the Securities and
     Exchange  Commission.

     a.   Upon  the  exercise  of  all  of  these options by the Consultant, the
          Company  shall  have  the  right to hold a common stock certificate(s)
          representing  37,500  options  exercised, on behalf of the Consultant,
          for  up to 90 calendar days after exercise by the Consultant. Further,
          the Company shall have the right to hold a common stock certificate(s)
          representing  112,500  options exercised, on behalf of the Consultant,
          for  up  to  180  calendar  days  after  exercise  by  the Consultant.

By: /s/ Michael  Dewar
    ------------------------------------------
    Michael  Dewar,  Chief  Operating  Officer
    International  Wireless,  Inc.

By: /s/  Simon  Pelman
    ------------------------------------------
    Simon  Pelman,  Consultant

<PAGE><PAGE>

                                                                    EXHIBIT 10.4

                        DEVELOPMENT AND LICENSE AGREEMENT

                                     between

                          DISCOVERY THERAPEUTICS, INC.

                                       and

                            FUJISAWA HEALTHCARE, INC.

                        DEVELOPMENT AND LICENSE AGREEMENT

--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The
copy filed herewith omits the information subject to the confidentiality
request. Omissions are designated as *. A complete version of this exhibit has
been filed separately with the Securities and Exchange Commission.
--------------------------------------------------------------------------------

<PAGE>

                                TABLE OF CONTENTS

                                                                    PAGE
                                                                    ----

1.   DEFINITIONS ...................................................  2
     1.1    "A1 Agonist Library" ...................................  2
     1.2    "Affiliate" ............................................  2
     1.3    "Back-up Compound(s)" ..................................  2
     1.4    "Back-up Compound Notice Period" .......................  2
     1.5    "Compound" .............................................  2
     1.6    "Data" .................................................  2
     1.7    "Development Plan" .....................................  2
     1.8    "Diligent Efforts" .....................................  2
     1.9    "DTI Data" .............................................  2
     1.10   "DTI Data Product" .....................................  2
     1.11   "DTI IND" ..............................................  2
     1.12   "DTI Know-How" .........................................  2
     1.13   "DTI Patents" ..........................................  3
     1.14   "DTI's Pre-clinical Studies" ...........................  3
     1.15   "DTI Target Dates" .....................................  3
     1.16   "Experimentation" ......................................  3
     1.17   "FDA" ..................................................  3
     1.18   "Field" ................................................  3
     1.19   "FTE" ..................................................  3
     1.20   "Fujisawa Data" ........................................  3
     1.21   "Fujisawa Data Product" ................................  3
     1.22   "Fujisawa Technology" ..................................  3
     1.23   "IND" ..................................................  4
     1.24   "Injectable Product" ...................................  4
     1.25   "Injectable Protocol" ..................................  4
     1.26   "Joint Management Committee" or "JMC" ..................  4
     1.27   "Jointly Owned Patents" ................................  4
     1.28   "Licensed Product(s)" ..................................  4
     1.29   "NDA" ..................................................  4
     1.30   "Net Sales" ............................................  4
     1.31   "Non-Injectable Product" ...............................  5
     1.32   "Non-Injectable Protocol" ..............................  5
     1.33   "Phase I Trial" ........................................  5
     1.34   "Phase II Trial" .......................................  5
     1.35   "Phase III Trial" ......................................  5
     1.36   "Primary Indications" ..................................  5
     1.37   "PTO" ..................................................  5
     1.38   "Regulatory Approval" ..................................  5
     1.39   "Remaining Compounds" ..................................  5
     1.40   "Territory" ............................................  5
     1.41   "Third Party" ..........................................  5

<PAGE>

2. LICENSE GRANT ..........................................................    5
   2.1  License to Fujisawa ...............................................    5
   2.2  Sublicenses .......................................................    6
   2.3  Research License ..................................................    6
   2.4  Retained Rights ...................................................    6
   2.5  DTI Restrictive Covenant ..........................................    6
   2.6  Fujisawa Restrictive Covenant .....................................    6
   2.7  Disclosure of DTI Know-How ........................................    6
   2.8  Distribution Through Third Parties ................................    7
   2.9  Exclusivity .......................................................    7

3. PRODUCT DEVELOPMENT ....................................................    8
   3.1  General ...........................................................    8
   3.2  Engagement of Third Parties .......................................    8
   3.3  Joint Management Committee ........................................    8
   3.4  Development Plan ..................................................    8
   3.5  Diligence .........................................................    9
   3.6  Abandoned Products ................................................   10
   3.7  Clinical and Regulatory Matters ...................................   11
   3.8  Back-up Compounds .................................................   12
   3.9  Exchange of Information Between the Parties and Access to Data ....   13

4. COMMERCIALIZATION ......................................................   14
   4.1  General ...........................................................   14
   4.2  Failure to Launch .................................................   14
   4.3  Distribution and Promotion ........................................   15
   4.4  Trademarks ........................................................   15
   4.5  Exchange of Adverse Event Information .............................   15
   4.6  Regulatory Actions; Product Recalls; Product Withdrawals ..........   16

5. PAYMENTS AND ROYALTIES .................................................   17
   5.1  License Fees ......................................................   17
   5.2  Development Costs .................................................   17
   5.3  Milestones ........................................................   17
   5.4  Earned Royalties ..................................................   18
   5.5  Royalties to Fujisawa .............................................   18
   5.6  Additional Royalties to DTI .......................................   19
   5.7  Royalty Term ......................................................   19
   5.8  Withholding Taxes .................................................   20
   5.9  Blocked Currency ..................................................   20
   5.10 Royalty Payments and Reports ......................................   20
   5.11 Currency; Exchange Rate ...........................................   20
   5.12 Accounting ........................................................   21

6. MANUFACTURING ..........................................................   21
   6.1  General ...........................................................   21
   6.2  Quality Assurance .................................................   21

                                       ii

<PAGE>

7.  REPRESENTATIONS AND WARRANTIES; DISCLAIMERS ............................. 22
    7.1 Representations and Warranties. ..................................... 22
    7.2 Warranty Disclaimer ................................................. 23

8.  INDEMNITY AND INSURANCE ................................................. 23
    8.1 Indemnification by Fujisawa ......................................... 23
    8.2 Indemnification by DTI .............................................. 24
    8.3 Indemnification Procedure ........................................... 24
    8.4 Insurance ........................................................... 24

9.  PROTECTION OF PATENTS; CLAIMS OF INFRINGEMENT ........................... 24
    9.1 Ownership of Intellectual Property .................................. 24
    9.2 Infringement of DTI Patents. ........................................ 25
    9.3 Defense and Settlement of Third Party Claims of Patent Infringement.. 26
    9.4 Prosecution and Maintenance of DTI Patents .......................... 26
    9.5 Prosecution and Maintenance of Joint Patents ........................ 27

10. CONFIDENTIALITY ......................................................... 27
    10.1 Information ........................................................ 27
    10.2 Exceptions ......................................................... 27
    10.3 Permitted Disclosures .............................................. 28
    10.4 Disclosure of Agreement; Press Releases ............................ 28

11. TERM AND TERMINATION .................................................... 28
    11.1 Term ............................................................... 28
    11.2 Early Termination for Material Breach .............................. 29
    11.3 Termination for Bankruptcy ......................................... 29
    11.4 Early Termination by Fujisawa. ..................................... 29
    11.5 Termination of Entire Agreement .................................... 30
    11.6 Effect of Partial Termination ...................................... 30
    11.7 Effect of Early Termination. ....................................... 31
    11.8 Accrued Obligations ................................................ 33
    11.9 Surviving Obligations .............................................. 33

12. ASSIGNMENT .............................................................. 33

13. DISPUTE RESOLUTION ...................................................... 33
    13.1 Discussion ......................................................... 33
    13.2 Alternative Dispute Resolution ..................................... 34
    13.3 Mediation. ......................................................... 34
    13.4 Arbitration ........................................................ 35
    13.5 Procedure .......................................................... 35

14. GENERAL ................................................................. 36
    14.1 Notices ............................................................ 36
    14.2 Retained Rights .................................................... 37
    14.3 Consents Not Unreasonably Withheld or Delayed ...................... 37
    14.4 Force Majeure ...................................................... 37

                                       iii

<PAGE>

   14.5   Further Actions ................................................... 37
   14.6   No Trademark Rights ............................................... 37
   14.7   Waiver ............................................................ 37
   14.8   Independent Contractors ........................................... 38
   14.9   Entire Agreement .................................................. 38
   14.10  Governing Law ..................................................... 38
   14.11  Severability ...................................................... 38
   14.12  Counterparts ...................................................... 38

                                       iv

<PAGE>

                        DEVELOPMENT AND LICENSE AGREEMENT

                                     between

                          DISCOVERY THERAPEUTICS, INC.

                                       and

                            FUJISAWA HEALTHCARE, INC.

                        DEVELOPMENT AND LICENSE AGREEMENT

         THIS DEVELOPMENT AND LICENSE AGREEMENT (the "Agreement"), dated as of
July 29, 1999 (the "Effective Date"), is made by DISCOVERY THERAPEUTICS, INC., a
Delaware corporation having a principal place of business at 2028 Dabney Road,
Suite E-17, Richmond, VA 23230-3311, U.S.A. ("DTI"), and FUJISAWA HEALTHCARE,
INC., a Delaware corporation having a principal place of business at Parkway
North Center, Three Parkway North, Deerfield, Ill. 60015 ("Fujisawa"). DTI and
Fujisawa are sometimes referred to herein individually as a "Party" and
collectively as the "Parties."

                                   WITNESSETH

         WHEREAS, DTI owns certain patents, patent applications and know-how
relating to DTI's proprietary adenosine receptor agonist DTI 0009 and various
other compounds;

         WHEREAS, DTI has successfully advanced DTI 0009 through preclinical
development and is about to or has commenced Phase I clinical trials;

         WHEREAS, Fujisawa is a health care company with development and
marketing activities in North America, and which desires to obtain additional
potential drug products to sell in the United States and Canada for the
treatment, through an injectable mode of administration, of paroxysomal
supraventricular tachycardias ("PSVT") and atrial fibrillation and flutter
("AFIB/F") in humans, among other potential indications; and

         WHEREAS, DTI wishes to license the rights, upon the terms and
conditions contained in this Agreement, to Fujisawa in the United States and
Canada to develop and commercialize pharmaceutical products containing DTI 0009
or Back-up Compounds (as hereinafter defined) for the treatment, through an
injectable mode of administration, of all diseases in humans, including but not
limited to PSVT and AFIB/F.

         NOW, THEREFORE, in consideration of the above premises and covenants
contained herein, the Parties agree as follows:

<PAGE>

1.   DEFINITIONS

     1.1   "A1 Agonist Library" means all of the Al agonist compounds that are
owned, licensed to or controlled by DTI and that are covered by one or more
claims within the DTI Patents.

     1.2   "Affiliate" means any entity that directly or indirectly Owns, is
Owned by or is under common Ownership with, a Party to this Agreement. "Owns,"
"Owned" or "Ownership" means direct or indirect possession of at least fifty
percent (50%) of the outstanding voting securities of a corporation or a
comparable equity interest in any other type of entity.

     1.3   "Back-up Compound(s)" means any compound that Fujisawa selects from
the A1 Agonist Library pursuant to Section 3.8, for use as provided in Section
3.8(b).

     1.4   "Back-up Compound Notice Period" shall have the meaning ascribed to
it in Section 3.8(a)(i).

     1.5   "Compound" means the compound known as DTI 0009, which is further
described in Exhibit A attached hereto.

     1.6   "Data" shall mean any and all data, reports, and/or documentation (or
analyses thereof) generated in connection with clinical trials, preclinical
studies or other investigations of the Compound or any Back-up Compound.

     1.7   "Development Plan" means the development plan, as may be amended,
that is described in Section 3.4.

     1.8   "Diligent Efforts" means the carrying out of obligations in a
sustained manner consistent with the efforts a Party devotes to a product of
similar market potential, profit potential or strategic value resulting from its
own research efforts, based on conditions then prevailing. Diligent Efforts
requires, at a minimum, that: (i) the Party promptly assigns responsibility for
such obligations to specific employee(s) who are held accountable for progress
and monitor such progress on an on-going basis, (ii) the Party sets and
consistently seeks to achieve specific and meaningful objectives for carrying
out such obligations, and (iii) the Party consistently makes and implements
decisions and allocates resources designed to advance progress with respect to
such objectives.

     1.9   "DTI Data" shall have the meaning ascribed to it in Section 3.9.

     1.10  "DTI Data Product" shall have the meaning ascribed to it in Section
5.6.

     1.11  "DTI IND" shall have the meaning ascribed to it in Section 2.7(b).

     1.12  "DTI Know-How" means any and all pre-clinical, clinical, technical,
scientific, medical, sales and marketing information, data, knowledge, methods,
inventions, materials, practices and trade secrets including, but without
limitation, manufacturing processes and techniques, quality control information
and procedures and pharmacological, toxicological and

                                       2

<PAGE>

clinical test data and results, which is (i) owned by, controlled by, or
licensed to DTI as of the Effective Date or is invented or developed by or
licensed to DTI during the term of this Agreement (and available for sublicense
to or otherwise able to be disclosed to Fujisawa), and (ii) necessary for,
useful for or used in the manufacture, use, development, registration,
formulation, sale, or marketing of a Licensed Product in the Field. DTI Know-How
shall exclude the DTI Data, but shall include all Data generated by DTI in the
conduct of the Phase I Trial and DTI's Pre-Clinical Studies.

     1.13   "DTI Patents" means any and all patents, patent applications or
patents issuing from such applications, and all reissues, reexaminations,
continuations, continuations-in-part, divisionals, extensions, or Supplemental
Protection Certificates, which cover the manufacture, use, sale, offer for sale,
importation or exportation of the Compound or Licensed Product in the Territory,
which are owned by, controlled by or licensed to DTI either directly or
indirectly, including specifically, but without limitation, U.S. Patent
No. 5,310,731, and including any Jointly Owned Patents. The DTI Patents are set
forth on Exhibit F, which shall be amended from time to time to include DTI
Patents issued or filed from and after the Effective Date.

     1.14   "DTI's Pre-clinical Studies" shall have the meaning ascribed thereto
in Section 7.1(x).

     1.15   "DTI Target Dates" shall have the meaning ascribed to it in Section
3.4.

     1.16   "Experimentation" shall mean the conduct of scientific experiments
with respect to a compound in the Al Agonist Library, as evidenced by laboratory
notebook entries regarding such experiments.

     1.17   "FDA" means the United States Food and Drug Administration or its
equivalent in Canada, or any successor entity thereto.

     1.18   "Field" means the diagnosis, prevention and/or treatment of
diseases, syndromes or conditions in humans, including but not limited to PSVT
and AFIB/F.

     1.19   "FTE" is an acronym that stands for Full Time Equivalent, which
shall mean one or more researchers employed by DTI and possessing skills and
experience necessary to carry out applicable tasks described in Section 2.7(a)
with such time and effort to constitute one such researcher working the
equivalent of a full year of effort on a full time basis (not less than 40 hours
per week).

     1.20   "Fujisawa Data" shall have the meaning ascribed to it in Section
3.9.

     1.21   "Fujisawa Data Product" shall have the meaning ascribed to it in
Section 5.5.

     1.22   "Fujisawa Technology" means, to the extent necessary or useful to
make, use or sell a Licensed Product, all patents and patent applications and
information, trade secrets, data, inventions and know-how, owned by, controlled
by, or licensed to Fujisawa (with the right to sublicense) provided that
Fujisawa Technology shall only include such patents, patent applications,
information, trade secrets, data (including the Fujisawa Data), inventions and

                                        3

<PAGE>

know-how as were developed or owned by or licensed to Fujisawa: (a) from and
after the date of this Agreement; and (b) solely in connection with the Compound
and Back Up Compound. Fujisawa Technology shall not include the DTI Patents, DTI
Know-How and any and all patents, patent applications, information, trade
secrets, data, inventions and/or know how developed, owned or licensed by
Fujisawa in connection with and/or relative to Fujisawa's license arrangements
with Medco Research, Inc. Fujisawa Technology shall not include trademarks for
any Licensed Products, which shall be handled in accordance with Section 4.4.

        1.23    "IND" means an investigational new drug application, as defined
by the FDA in 21 CFR Part 312, or the equivalent application in Canada.

        1.24    "Injectable Product" means a product that is formulated solely
for intravenous, subcutaneous, intracoronary, intraarterial or intramuscular
administration.

        1.25    "Injectable Protocol" shall have the meaning ascribed to it in
Section 2.7(b).

        1.26    "Joint Management Committee" or "JMC" means the Committee
described in Section 3.3.

        1.27    "Jointly Owned Patents" shall be defined as set forth in Section
9.5.

        1.28    "Licensed Product(s)" means an Injectable Product that contains
as its active ingredient the Compound or a Back-up Compound.

        1.29    "NDA" means a New Drug Application as defined by the FDA in 21
 C.F.R. Part 314, or its equivalent in Canada.

        1.30    "Net Sales" means gross amounts invoiced for the sale of the
Licensed Product(s) in finished package form sold by Fujisawa or its
sublicensees, less

                (a) any and all normal and customary trade and quantity
discounts, customary allowances actually granted to purchasers of the Licensed
Product(s) for returns and recalled Licensed Product (whether in the form of
either a credit or free replacements actually given in place of returned or
recalled Licensed Product(s), allowances to end users (whether in the form of
either a credit or free product) participating in Fujisawa Sponsored Trial
Support, capitation, market share or stop loss agreements, or other compliance
incentive programs, Medicaid rebates given pursuant to agreement with U.S.
Department of Health and Human Services and any other rebates given pursuant to
government based rebate programs (including without limitation state and local
rebate programs) whether currently in effect or which become effective during
the term of this Agreement, administrative fees to managed health care
organizations (including but not limited to Group Purchasing Organizations,
HMO's etc.), chargeback and reporting rebates paid to wholesalers and other
distributors;

                (b) freight expenses for shipping finished product to such
purchasers; and

                (c) excise and value added taxes applicable to sales of the
Licensed Products) in finished package form which Fujisawa has to pay or absorb
on such sales.

                                       4

<PAGE>

No deductions shall be made for commissions paid to individuals whether they be
with independent sales agencies or regularly employed by Fujisawa, and/or its
sublicensee(s) and on its or their payroll, or for cost of collections. Licensed
Products shall be considered "sold" when billed out or invoiced. Sale or
transfer to an Affiliate or sublicensee for re-sale by such Affiliate or
sublicensee shall not be considered a sale for the purpose of this provision,
but the resale by such Affiliate or sublicensee to a Third Party shall be a sale
for such purposes.

        1.31 "Non-Injectable Product" means any product which is (i) not an
Injectable Product, including, without limitation, those formulated for
administration through the alimentary canal, including by mouth or for use in
the mouth through sublingual absorption and/or absorption through submucosal or
buccal tissue, and through transdermal administration, including absorption
through rectal tissue and (ii) which contains as its active ingredient a
Compound or a Back-up Compound.

        1.32    "Non-Injectable Protocol" shall have the meaning ascribed to it
in Section 2.7(b).

        1.33    "Phase I Trial" means the Phase I clinical trial to be performed
by DTI pursuant to the Protocol Number DTI 0009-001.

        1.34    "Phase II Trial" means the first dose finding trial in patients.

        1.35    "Phase III Trial" means the first controlled clinical trial
after dose finding trials.

        1.36    "Primary Indications" means PSVT and AFIB/F.

        1.37    "PTO" means the United States Patent and Trademark Office.

        1.38    "Regulatory Approval" means all approvals by the applicable
regulatory agency in the relevant country of the Territory necessary to market
and sell a Licensed Product.

        1.39    "Remaining Compounds" shall have the meaning ascribed to it in
Section 3.8(a)(ii).

        1.40    "Territory" means the United States and its territories and
possessions, and Canada.

        1.41    "Third Party" means any entity other than DTI or Fujisawa.

2.      LICENSE GRANT

        2.1     License to Fujisawa. Subject to the terms of Article 2 and the
other terms and conditions of this Agreement, and except as provided in Section
3.8(a)(iii), DTI hereby grants and Fujisawa hereby accepts an exclusive (even as
to DTI) license, with the right to sublicense as provided in Section 2.2, under
the DTI Patents and DTI Know-How to make, have made, use, sell, offer to sell,
have sold, export and import Licensed Products in the Field and in the
Territory. It is expressly understood by Fujisawa that the exclusivity grant in
this Section 2.1 is

                                       5

<PAGE>

subject to the provisions of Section 3.8(a)(iii), which may have the effect of
reducing the exclusivity in the Field for Licensed Products containing certain
Back-up Compounds from all indications to only the Primary Indications.

        2.2     Sublicenses. Fujisawa shall have the right to grant sublicenses
at any time to a Third Party with respect to any rights conferred upon Fujisawa
under this Agreement; provided, however, that (i) any such sublicense shall be
subject in all respects to the restrictions, royalty and other payment
obligations, reports, and other provisions contained in this Agreement,
including but not limited to the obligations set forth in Article 3, (ii)
Fujisawa shall notify DTI of the identity of such sublicensee promptly on
execution of the sublicense; and (iii) subject to any confidentiality
restrictions set forth in such sublicense agreements, Fujisawa shall forward to
DTI a copy of any and all sublicense agreements promptly upon execution by the
parties thereto.

        2.3     Research License. Subject to the conditions and limitations set
forth in this Agreement, Fujisawa hereby grants to DTI an exclusive (except as
to Fujisawa), paid-up license, under the Fujisawa Technology to conduct research
and development activities for the Phase I Trial with respect to Licensed
Products pursuant to the Development Plan.

        2.4     Retained Rights. Subject to Section 2.5, DTI retains any and all
rights under the DTI Patents and DTI Know-How not expressly licensed to Fujisawa
under this Agreement, specifically including, but without limitation, any and
all rights to make, have made, use, sell, have sold, export or import (i)
compounds covered by one or more claims in the DTI Patents other than the
Compound and any Back-up Compound selected pursuant to Section 3.8 for any use,
(ii) any Non-Injectable Products and (iii) Licensed Products outside of the
Territory.

        2.5     DTI Restrictive Covenant. DTI covenants that during the term of
this Agreement it shall not, license (in whole or in part), conduct, fund,
develop or participate in, directly or indirectly through one or more Third
Parties, the research, development, distribution or commercialization in the
Territory of any Injectable Products to treat the Primary Indications. DTI
further covenants that it shall not, during the term of this Agreement, license
(in whole or in part), conduct, fund, develop or participate in, directly or
indirectly through one or more Third Parties, the research, development,
distribution or commercialization in the Territory of any Licensed Products in
the Field, subject to the terms of Section 3.8(a)(iii) and the last sentence of
Section 2.1 DTI shall be further restricted in its development and
commercialization efforts as set forth in Section 3.8(a)(i). The provisions of
this Section 2.5 shall not apply to the extent that DTI obtains from Fujisawa
the right to develop and commercialize a Licensed Product in the Field in the
Territory, whether pursuant to Section 3.5(b), 3.6, 4.2(a), or Article 11.

        2.6     Fujisawa Restrictive Covenant. Fujisawa covenants that it shall
not use or practice the DTI Patents or DTI Know-How to make, offer to sell, have
made, use, sell, have sold, export or import Licensed Products in the United
States for any uses except as expressly granted in Section 2.1.

        2.7     Disclosure of DTI Know-How.

                (a)     Upon signing the Agreement, and subject to the
obligations of confidentiality set forth in this Agreement, DTI shall disclose
to Fujisawa and provide copies of

                                       6

<PAGE>

all documentation of DTI Know-How, including, but not limited to, all of DTI's
data regarding its Al Agonist Library and the DTI IND. Except as provided in
Section 3.8(a)(iv), DTI shall also promptly provide to Fujisawa a copy of any
additional or new documents covering the DTI Know-How that may come into DTI's
possession after the Effective Date, including, in (a) particular any Data
generated in connection with the Phase I Trial. In addition, DTI shall make
available to Fujisawa, upon reasonable notice and during normal business hours,
the reasonable assistance of DTI's employees who are knowledgeable about the DTI
Know-How and DTI Patents in order to facilitate Fujisawa's efforts to develop
and commercialize Licensed Products. DTI shall provide the assistance of at
least one (1) FTE for a period of 1 year from the Effective Date, and thereafter
at and for such times as Fujisawa may request. Fujisawa may, at its option,
request that DTI provide and DTI shall provide, upon such request, such
additional FTEs. Fujisawa shall reimburse DTI for such assistance at a rate
equivalent to * annually per FTE, payable in equal quarterly installments
commencing ninety (90) days from the Effective Date, but may terminate its right
to receive DTI's assistance at any time after the first anniversary of the
Effective Date.

           (b)   The Parties acknowledge and agree that an IND was submitted by
DTI to the FDA on July 12, 1999 covering both the Licensed Product and the
Non-Injectable Product (the "DTI IND"). The Protocol Number for the Phase I
Trial for the Licensed Product is DTI-0009-001 ("Injectable Protocol") and the
Protocol Number for the Phase I Trial for the Non-Injectable Product is
DTI-0009-002 ("Non-Injectable Protocol"). DTI will, at Fujisawa's expense,
transfer to Fujisawa the DTI IND together with any and all regulatory files,
reports, data, written information and related documentation associated with
such submission and promptly notify FDA in writing of such transfer. DTI will
make such transfer within thirty (30) days after the date DTI completes the
Phase I Injectable Protocol for the Licensed Product or within 30 days after the
date Fujisawa exercises its option under Section 3.5(a)(ii), whatever date is
earlier; provided however, that if transfer is delayed due to actions, lack of
action, or policies of FDA, then the period for transfer shall be extended by
the length of the relevant delay. The Parties acknowledge and agree that if such
transfer is delayed due to the actions, lack of action or policies of the FDA or
DTI, then the "Critical Target Dates" (as hereinafter defined) or other
obligations due from Fujisawa shall be extended by the length of the relevant
delay. The Parties further acknowledge and agree that once the DTI IND is
transferred to Fujisawa: (i) Fujisawa will notify the FDA that the DTI IND does
not cover the Non-Injectable Product and/or the Non-Injectable Protocol; (ii)
except as otherwise provided in this Agreement, Fujisawa will have no
responsibility whatsoever with respect to the Non-Injectable Protocol; (iii) at
the same time as such transfer, DTI shall submit its own IND for the
Non-Injectable Protocol; and (iv) the Parties shall be entitled to cross
reference the IND of the other party, once DTI's IND for the Non-Injectable
Product, has been allowed by the FDA.

     2.8   Distribution Through Third Parties. DTI grants Fujisawa the right to
distribute Licensed Products through Third Party distributors in the Territory;
provided, that Fujisawa shall use distributors with expertise and distribution
capacity appropriate to the Licensed Product.

     2.9   Exclusivity. For the purposes of this Article 2, the phrase
"exclusive except as to" shall mean that the licensee and the licensor shall
share the rights granted in the relevant license grant, and the phrase
"exclusive even as to" shall mean that the grantor shall retain none

--------------------------------------------------------------------------------

 *  Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.

--------------------------------------------------------------------------------

                                       7

<PAGE>

of the rights granted in the relevant license grant. Rights that are sublicensed
pursuant to this Article 2 shall be exclusive only to the extent the licensor
holds exclusive rights.

3.   PRODUCT DEVELOPMENT

     3.1   General. DTI shall be responsible for conducting the Phase I Trial
for the Compound for the Primary Indications. Fujisawa shall be responsible for
all other aspects pertaining to the development of, and obtaining Regulatory
Approval for, the Licensed Products in the Territory. Subject to Section 3.5(c),
Fujisawa shall have the final decision-making authority with respect to all
aspects of the development of the Licensed Products.

     3.2   Engagement of Third Parties. In the course of performing its
development obligations under this Agreement, either Party may engage Third
Parties to perform certain development activities, provided that (i) the other
Party is informed of the use and identity of Third Parties for the relevant
activity, and (ii) each Party obtains contractual undertakings from such Third
Parties (including in particular with respect to quality assurance, compliance
with law, and confidentiality) as may be applicable to, and customary in the
pharmaceutical industry for, the relevant activity to be performed by such Third
Party.

     3.3   Joint Management Committee. Promptly after the Effective Date, the
Parties shall form a Joint Management Committee ("JMC") which shall consist of
two (2) representatives of each Party with expertise in such disciplines as
clinical, regulatory affairs, manufacturing or marketing. One of the Fujisawa
representatives shall serve as the chairperson of the JMC. All decisions of the
JMC shall be made by a majority vote of the representatives on the JMC;
provided, that Fujisawa shall cast the decisive tie-breaking vote in the event
that the JMC is unable to come to a decision on any matter, subject to Section
3.5(c). Either Party may bring additional non-voting representatives to the
meetings of the JMC so long as such Party provides prior notice at the time
Fujisawa is required to provide an agenda under this Section 3.3 to the other
Party that it intends to bring such representatives. The JMC shall meet
regularly (but in no event less than three times per year) at such times and at
such locations as shall be mutually agreed by the Parties. The JMC shall review
development activities of DTI and Fujisawa in accordance with the Development
Plan including, but not limited to, the choice of contract research
organization, consultants, Third Party contract manufacturers and assignment of
development activities, the development of new formulations and other product
changes, and communication with FDA and other Third Parties. At least 10
business days prior to each regularly scheduled meeting of the JMC, Fujisawa and
DTI shall provide a written status report to the JMC concerning its progress
with respect to the Development Plan and Fujisawa shall provide an agenda for
the upcoming meeting. Promptly after each meeting of the JMC, the chairperson
shall provide minutes of such meeting.

     3.4   Development Plan. Attached to this Agreement as Exhibit B is a
Development Plan setting forth (i) DTI's anticipated timeline for commencement
and completion of the Phase I Trial (the "DTI Target Dates"); and (ii)
Fujisawa's anticipated timeline for the development program for the Licensed
Product for the treatment of the Primary Indications in the United States,
including target dates for key clinical and regulatory events ("Critical Target
Dates"). The Critical Target Dates shall include, without limitation, the date
by which Fujisawa shall

                                       8

<PAGE>

enroll the first patient in Phase II and III clinical trials for the Licensed
Product for the treatment of the Primary Indications (the "Clinical Target
Dates"), and the date of submission of applications for Regulatory Approval in
the United States. Fujis awa anticipates the commercial launch date for each
Licensed Product to be *from the date of Regulatory Approval for each such
Licensed Product. The Development Plan may be amended from time to time in
writing by the JMC, subject to Section 3.5(c). Any amended Development Plan
shall be attached hereto at Exhibit B.

     3.5   Diligence.

           (a)   Development Efforts.

                 (i)   Fujisawa shall use Diligent Efforts to carry out
development of the Licensed Product for the treatment of the Primary Indications
in accordance with the Development Plan. If Fujisawa determines that it will be
unable to meet any of the Critical Target Dates identified in the Development
Plan within six (6) months after the date specified in such Development Plan, it
shall notify the JMC within thirty (30) days of such determination. The JMC
shall develop a revised Development Plan for the Licensed Product which shall
include new Critical Target Dates, provided however, that DTI's JMC
representatives must agree to the new Critical Target Dates. In the event DTI's
voting representatives do not agree to the Critical Target Dates set forth in
the revised Development Plan, then either Party may, at its election, proceed
under Section 3.5(c).

                 (ii)  DTI shall use Diligent Efforts to carry out the Phase I
Trial in accordance with the Development Plan. If DTI fails to, or expects that
it will fail to, meet any DTI Target Date, by more than three (3) months,
Fujisawa may, at its option, assume control of and complete the Phase I Trial.
In such event, the Parties shall cooperate fully and take all necessary steps to
obtain the necessary Regulatory Approvals to effectuate the transfer of the
Phase I Trial.

           (b)   Extended Delay. Subject to Section 11.5, if Fujisawa (i) fails
to meet any of the Clinical Target Dates then in effect for the Licensed Product
for a given Primary Indication within 12 months after the relevant Clinical
Target Date specified in the Development Plan for such Primary Indication, or
(ii) fails to submit for Regulatory Approval of that Licensed Product for such
Primary Indication in the United States within 18 months after the date
specified for such submission in the Development Plan with respect to such
Licensed Product, then DTI may terminate Fujisawa's rights under this Agreement
with respect to such Licensed Product for such particular Primary Indication. In
such event, Fujisawa shall promptly transfer to DTI all INDs or their Canadian
equivalent and other relevant regulatory filings as it may hold with respect to
that Licensed Product for the particular Primary Indication, and any information
as Fujisawa may possess which is necessary or useful to gain Regulatory Approval
for and to commercialize such Licensed Product in the Territory for such Primary
Indication. Such transfer shall be without cost to DTI, provided however that
DTI shall pay any governmental filing or transfer fees that may be required.
Fujisawa also grants to DTI, effective only in the event its rights to such
Licensed Product for such Primary Indication are terminated under this Section
3.5(b), an exclusive fully paid and royalty-free (subject to DTI's obligations
under Section 5.5)

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       9

<PAGE>

license under the Fujisawa Technology to make, have made, use, import, export,
offer for sale and sell such Licensed Product for such Primary Indication and,
to the extent it has the right to do so, grant to DTI a sublicense under any
Third Party licenses to which Fujisawa has rights, to the extent that such
rights are necessary or useful to make, have made, use, import, export, offer
for sale and sell the Licensed Product. DTI shall thereafter assume the cost of
maintaining its proportionate share of such Third Party license and shall
perform such obligations of Fujisawa under such license agreement as are
applicable to the relevant Licensed Product. To the extent such Third Party
license is no longer applicable or useful to Fujisawa, Fujisawa shall assign to
DTI all of its rights and obligations thereunder, rather than grant a sublicense
under, such license agreement. The JAM shall have no authority with respect to
the development and commercialization of a Licensed Product as to which rights
have reverted to DTI under this Section 3.5(b).

          (c) Disputes Regarding Critical Target Dates. If the Parties are
unable to reach agreement as to the Critical Target Dates in any proposed
revision to the Development Plan, then either Party may submit the issue for
binding arbitration pursuant to Section 13.4, provided that such arbitration
shall be conducted before an expert or expert panel in the field of clinical
drug development (rather than before a judge or an attorney). Such expert may be
mutually agreed upon by the Parties, but if no such expert is agreed upon within
ten (10) days after the written notice from one Party to the other, then each
Party shall promptly select one expert, and those two experts shall select a
third expert, which shall comprise the panel. Notwithstanding any provisions
concerning duration of arbitration proceedings set forth in Section 13.4, the
panel shall meet with the Parties within thirty (30) days of selection to
examine such proposed revisions to the Development Plan and shall hear the views
and proposals of each Party. Within ten (10) days thereafter, it shall render
its binding decision by majority vote, as to whether the Critical Target Dates
proposed in the revised Development Plan are reasonable under all of the
circumstances. The Parties shall share equally in the cost of the expert or
expert panel, including any fees and expenses payable to the experts. If the
expert or expert panel determines that the proposed Critical Target Dates are
not reasonable, then Fujisawa will be held to the Critical Target Dates set
forth in the most recently approved Development Plan, subject to any
modifications agreed to by DTI. If such Critical Target Dates have passed as of
the date of the expert's or expert panel's decision, the panel shall set new
Critical Target Dates, taking into consideration the views and proposals
presented by the Parties in the course of the proceedings conducted under this
Section 3.5(c).

     3.6  Abandoned Products. Subject to Section 11.5, if Fujisawa decides, at
any time or from time to time, that it does not desire to commence or continue
research, development or commercialization activities, including without
limitation, conducting clinical development or seeking Regulatory Approval of a
Licensed Product (for either of the Primary Indications or any other
indications) or to sublicense any of the foregoing activities, it shall provide
written notice to DTI within thirty (30) days of such decision. Upon receipt of
such notice, DTI may, at its election, terminate Fujisawa's rights under this
Agreement with respect to such Licensed Product for such indication. In such
event, Fujisawa shall (i) promptly transfer to DTI all INDs and their Canadian
equivalent (as applicable) and other relevant regulatory filings as it may hold
with respect to such Licensed Product for such indication, and any and all
written information as Fujisawa may possess which is useful to gain Regulatory
Approval for and to commercialize

                                       10

<PAGE>

such Licensed Product for such indication. Such transfer shall be without cost
to DTI, provided however that DTI shall pay any governmental filing or transfer
fees that may be required; (ii) grant to DTI an exclusive fully paid and
royalty-free license under the Fujisawa Technology to make, have made, use,
import, offer for sale and sell (subject to DTI's obligations under Section 5.5)
such Licensed Product for such indication in the Territory, and (iii) to the
extent it has the right to do so, grant to DTI a sublicense under any Third
Party licenses to which Fujisawa has rights, to the extent that such rights are
necessary or useful to make, have made, use, import, offer for sale and sell
such Licensed Product for such indication in the Territory. DTI shall thereafter
assume the cost of maintaining its proportionate share of such Third Party
license and shall perform such obligations of Fujisawa under such license
agreement as are applicable to the relevant Licensed Product. To the extent such
Third Party license is no longer applicable or useful to Fujisawa, Fujisawa
shall assign to DTI all of its rights and obligations thereunder, rather than
grant a sublicense under, such license agreement. The JMC shall have no
authority with respect to the development and commercialization of a Licensed
Product as to which rights have reverted to DTI under this Section 3.6.

     3.7  Clinical and Regulatory Matters.

          (a) Clinical Trials. DTI shall be responsible for conducting the Phase
I Trial for the Compound for the Primary Indications under the Injectable
Protocol. Fujisawa shall be responsible for conducting, at its expense, all
other non-clinical and clinical studies necessary to obtain Regulatory Approval
of the Licensed Products in the Territory in accordance with the Development
Plan. The Parties shall conduct all such clinical trials in accordance with the
applicable laws and regulations of the country in which the data generated in
such clinical trial will be used to support an application for Regulatory
Approval of the relevant Licensed Product.

          (b) Drug Approval Applications Fujisawa shall be responsible for
preparing and submitting, at its expense, applications for Regulatory Approval
of the Licensed Products in the Territory. Fujisawa will submit the drug
approval applications in its own name and shall be responsible for obtaining
Regulatory Approval in the Territory and shall use Diligent Efforts to pursue
and obtain Regulatory Approval in the U.S.

          (c) Reporting. The Parties shall keep each other reasonably informed
as to the progress of the clinical trials for which each is responsible and drug
approval applications and of any issues raised by the relevant regulatory
agencies together with Fujisawa' proposed response. The Parties shall provide
each other with such reports on a periodic basis but not less than every four
(4) months at the regular meetings of the JMC. Each Party shall report to the
other concerning its progress with respect to clinical trials and applications
for Regulatory Approval, including providing the other with written notice as
soon as it has completed enrollment and dosed the last patient in each Phase I,
II and III clinical trial.

          (d) Responsibility. Subject to each Party's right to cross reference
the other's Data and regulatory filings under Section 3.9, any and all
regulatory applications and approvals in the Territory, including without
limitation the IND and NDA for each Licensed Product shall be held solely by
Fujisawa; provided, however, DTI shall hold the DTI IND until such time as it
completes the Phase I Trial, at which point it will transfer the DTI IND to
Fujisawa as provided

                                       11

<PAGE>

in Section 2.7 or 3.5(a)(ii). DTI shall be responsible for all regulatory
matters associated with the DTI IND during such time as it is the holder of the
DTI IND as provided above; provided, that Fujisawa shall be included in all
meetings and/or discussions with the FDA. DTI shall give Fujisawa at least 48
hours advance notice prior to any such meeting or discussion. DTI shall provide
Fujisawa within 72 hours after any such meeting or discussion any documentation
or correspondence from or with the FDA. After DTI transfers the DTI IND to
Fujisawa, Fujisawa shall have the exclusive responsibility for any and all
regulatory matters for each Licensed Product in each country comprising the
Territory, including without limitation contacts (written or oral) with the
applicable regulatory agency and submission of any and all information and/or
documents to such regulatory agency.

          (e)  Cooperation. DTI shall cooperate fully with Fujisawa in
Fujisawa's performance of its obligations under this Section 3.7, including
preparation for and participation with Fujisawa in responding to any
correspondence or requests received by Fujisawa from such regulatory authorities
to the extent DTI has relevant information or contributed to the regulatory
submission that is the subject of such inquiry.

     3.8  Back-up Compounds.

          (a)  Selection of Back-up Compounds.

               (i)     As required pursuant to Section 2.7, DTI will provide to
Fujisawa on the Effective Date all of its data and DTI Know-How regarding its A1
Agonist Library. During the sixty (60) day period following the Effective Date
(the "Back-up Compound Notice Period"), DTI covenants that it will not license
(in whole or in part), conduct, fund, develop or participate directly or
indirectly through, one or more Third Parties the research, development,
distribution or commercialization in the Territory of any compound in the A1
Agonist Library for use as an Injectable Product for any indication in the Field
(including without limitation PSVT and/or AFIB/F). During such Back-up Compound
Notice Period, Fujisawa may, at its option, provide written notice to DTI
designating up to three (3) compounds from the A1 Agonist Library as Back-up
Compounds. If Fujisawa so designates any Back-up Compound(s) during the Back-up
Compound Notice Period, DTI covenants that it will not license (in whole or in
part), conduct, fund, develop or participate in directly or indirectly through,
one or more Third Parties the research, development, distribution or
commercialization in the Territory of such Back-up Compound(s) for use as an
Injectable Product for any indication in the Field (including without limitation
PSVT and/or AFIB/F).

               (ii)    If, after the expiration of the Back-up Compound Notice
Period, Fujisawa does not make any such designation of Back-up Compounds, or
designates less than three (3) Back-up Compounds, DTI may, subject to the
restrictions in Section 2.5, license, conduct, fund, develop or participate in
directly or indirectly through one or more Third Parties, the research,
development, distribution or commercialization of any of the remaining compounds
in the A1 Agonist Library (hereafter the "Remaining Compound(s)") for any
indications other than the Primary Indications and in any formulation other than
Injectable Products.

               (iii)   At any time after the expiration of the Back-up Compound
Notice Period, and in the event Fujisawa has designated less than three (3)
Back-up Compounds during

                                       12

<PAGE>

the Back-up Compound Notice Period, Fujisawa may request in writing to designate
any Remaining Compounds as Back-up Compounds; provided, that the total number of
Back-up Compounds under this Agreement shall not exceed three (3). If Fujisawa
makes such Back-up Compound designation with respect to a Remaining Compound for
which DTI (or its sublicensee or contractee) has commenced Experimentation, then
(A) Fujisawa covenants that it will only develop and commercialize such Back-up
Compound(s) as Licensed Products to treat the Primary Indications in the
Territory and (B) the license grant to Fujisawa in Section 2.1 shall be
restricted with respect to any Licensed Product containing such Back-up Compound
such that DTI grants and Fujisawa accepts an exclusive (even as to DTI) license,
with right to sublicense as provided in Section 2.2, under the DTI Patents and
DTI Know-How to make, have made, sell, offer to sell, have sold, export and
import Licensed Products containing the selected Back-up Compound to treat only
the Primary Indications in the Territory. If, after the expiration of the
Back-up Compound Notice Period, Fujisawa designates as a Back-up Compound any
Remaining Compound for which DTI has not commenced Experimentation, then (A)
Fujisawa may develop and commercialize such Back-up Compound as a Licensed
Product in the Field pursuant to Section 3.8(b) and (B) the license grant to
Fujisawa in Section 2.1 shall not be restricted to Primary Indications and the
last sentence of Section 2.1 is not applicable in such event.

               (iv) In the event that DTI plans to undertake development or
commercialization of any Remaining Compound(s) with a Third Party, it shall
first provide written notice to Fujisawa along with the DTI Know-How with
respect to such Remaining Compound(s) as is reasonably necessary for Fujisawa to
assess its potential, and shall evaluate in good faith any offer that Fujisawa
makes to DTI with respect to Fujisawa's development and commercialization of
such Remaining Compound(s). Notwithstanding DTI's disclosure obligation pursuant
to Section 2.7 if DTI (or its sublicensee or contractee) has commenced
Experimentation for any Remaining Compound, DTI shall not be required to provide
Fujisawa with any additional DTI Know-How that DTI develops with respect to any
such Remaining Compound(s), except for DTI Know-How that relates to the Primary
Indications, in which case DTI shall be obligated to disclose promptly such DTI
Know-How.

          (b)  Substitution of Back-up Compounds. If during its development of
the Licensed Products, Fujisawa determines that the Compound that is the active
ingredient in a Licensed Product then under development is not suitable for
further development into a therapeutic product for use in humans, for safety,
efficacy, or other reasons, Fujisawa may then substitute a Back-up Compound in
place of the Compound. Such Back-up Compound shall then be considered a
"Compound" for purposes of this Agreement. In such event, and where the
substituted Compound was under development for the Primary Indications, the JMC
shall discuss appropriate changes to the Development Plan to accommodate the
changes in the pre-clinical, clinical and regulatory schedule necessitated by
such substitution. If the Parties are unable to agree on such changes, Fujisawa
shall be entitled to exercise its right to cast the decisive tie breaking vote
with respect to all matters except for those subject to dispute resolution
pursuant to Section 3.5(c).

     3.9  Exchange of Information Between the Parties and Access to Data.
Following the Effective Date and subject to the licenses set forth in this
Agreement, each Party shall own all Data generated by such Party in the course
of performing its obligations under this Agreement.

                                       13

<PAGE>

Fujisawa agrees to provide to DTI the right to access, inspect and copy any and
all Data generated by or for Fujisawa under this Agreement (the "Fujisawa
Data"). DTI agrees to provide to Fujisawa the right to access, inspect and copy
any and all Data generated by or for DTI after the Effective Date in connection
with its (or its sublicensees', to the extent such Data is made available to DTI
to further provide to Fujisawa) development of the Compound and/or any Back-up
Compounds as Non-Injectable Products or as Injectable Products outside the
Territory (the "DTI Data"). The Parties acknowledge and agree that DTI Data does
not include any Data generated in connection with the Phase I Trial, which such
Data shall be part of the DTI Know How. Fujisawa hereby grants to DTI the right
to use the Fujisawa Data and to refer to any submissions by Fujisawa for
Regulatory Approval or any Master Files held by Fujisawa with respect to
Licensed Products, in connection with any submissions for Regulatory Approval of
the Non-Injectable Products and/or submissions for Regulatory Approval of the
Injectable Products in countries outside of the Territory. In consideration of
such grant to DTI, DTI shall pay royalties to Fujisawa as specified in Section
5.5. DTI hereby grants Fujisawa the right to use the DTI Data and to refer to
any submissions by DTI for Regulatory Approval or any Master Files held by DTI
with respect to Non-Injectable Products, or Licensed Products outside the
Territory, in connection with Fujisawa's submissions for Regulatory Approval of
the Licensed Product in the Territory. In consideration for such grant to
Fujisawa, Fujisawa shall pay royalties to DTI as specified in Section 5.6.
Fujisawa's Data and DTI's Data shall be treated as "Information" pursuant to
Section 10.

4.   COMMERCIALIZATION

     4.1 General. Fujisawa shall be responsible for commercializing the Licensed
Products in the Territory and Fujisawa shall use Diligent Efforts to
commercialize the License Products in the U.S. Fujisawa shall be solely and
exclusively responsible for any and all matters regarding the commercialization
of Licensed Products, including without limitation matters such as advertising,
promotion and promotional materials, marketing, pricing, distribution and
customer operations.

     4.2 Failure to Launch.

         (a) Subject to 4.2(b) and Section 11.5, if Fujisawa or its sublicensee
does not launch a Licensed Product for treatment of each of the Primary
Indications in the United States within nine (9) months after obtaining
Regulatory Approval of such Licensed Product for such Primary Indication in the
United States, or sooner notifies DTI that it will not launch such Licensed
Product for such Primary Indication in the United States, Fujisawa's rights
under this Agreement with respect to such Licensed Product for such Primary
Indication and in the United States shall terminate upon the earlier of such
notice or the 1 year anniversary of the grant of Regulatory Approval, and DTI
shall be free to commercialize such Licensed Product for such Primary Indication
in the Territory. In such event, Fujisawa shall promptly transfer to DTI all
INDs, applications for Regulatory Approval and Regulatory Approvals, or their
Canadian equivalents (as applicable) as it may hold with respect to such
Licensed Product for such Primary Indication, and any written information as
Fujisawa may possess which is useful to gain Regulatory Approval for and to
commercialize such Licensed Product in the Territory for such Primary
Indication. Such transfer

                                       14

<PAGE>

shall be without cost to DTI, provided however that DTI shall pay any
governmental filing or transfer fees that may be required.

           (b)   Upon the occurrence of the events in Section 4.2(a), Fujisawa
shall also grant to DTI (i) an exclusive, fully-paid and royalty-free (subject
to DTI's obligations under Section 5.5) license under the Fujisawa Technology to
make, have made, use, import, export, offer for sale and sell such Licensed
Product for such Primary Indication in the U.S., and (ii) to the extent it has
the right to do so, a sublicense under any Third Party licenses to which
Fujisawa has rights, to the extent that such rights are necessary or useful to
make, have made, use, import, export, offer for sale and sell such Licensed
Product for such Primary Indication. DTI shall thereafter assume the cost of
maintaining its proportionate share of such Third Party license and shall
perform such obligations of Fujisawa under such license agreement as are
applicable to the relevant Licensed Products. To the extent such Third Party
license is no longer applicable or useful to Fujisawa, Fujisawa shall assign to
DTI all of its rights and obligations thereunder, rather than grant a sublicense
under, such license agreement.

      4.3  Distribution and Promotion.

           (a)   Pricing and Product Distribution. Fujisawa shall have the sole
right to set prices for Licensed Products and shall obtain all pricing approvals
as may be required. Fujisawa shall also be solely and exclusively responsible
for distribution of the Licensed Products in the Territory.

           (b)   Advertising and Promotion. Fujisawa will prepare or have
prepared, and have sole decision making authority over, any and all advertising
and education materials for the Licensed Products in the Territory.

      4.4  Trademarks. Fujisawa shall be responsible for developing,
registering, maintaining and defending any and all trademarks for the Licensed
Products, and shall own all such trademarks. Fujisawa shall, to the extent
practicable in Fujisawa's sole discretion, market and sell the Licensed Products
under a single trademark throughout the Territory. In the event that this
Agreement is terminated in its entirety pursuant to Section 11.4, upon the
request of DTI, the Parties shall negotiate in good faith the transfer or
license and the consideration therefor of all Fujisawa trademarks with respect
to the Licensed Products.

      4.5  Exchange of Adverse Event Information.

           (a)   Within sixty (60) days of their respective submission, Fujisawa
shall provide DTI with copies of that portion of the IND and NDA Annual Reports
submitted by Fujisawa with the FDA and any other similar reports submitted with
the applicable regulatory authority in Canada that address adverse event matters
arising from the use of Licensed Products. Fujisawa shall provide DTI with
copies of IND Safety Reports within three (3) days of their submission by
Fujisawa to the FDA. Following Regulatory Approval for each Licensed Product in
the United States (and Canada if applicable), Fujisawa shall provide DTI with
copies of those Periodic Adverse Event Reports submitted by Fujisawa to the FDA
or other applicable regulatory authority in Canada which relate to each Licensed
Product. Such adverse event

                                       15

<PAGE>

reports shall be provided by Fujisawa to DTI within thirty (30) days of their
submission by Fujisawa to the FDA or such other regulatory authority.

           (b)   Fujisawa shall provide DTI with copies of 15-Day Alert Reports
within three (3) days of their submission by Fujisawa to the FDA. Fujisawa shall
report these expedited reports on FDA MedWatch forms. Fujisawa shall notify the
contact person designated by DTI by fax at (804) 358-2451 or telephone at (804)
358-9468, as may be revised.

     DTI shall be responsible for reporting to Fujisawa all serious adverse
event reports occurring with each Licensed Product during the Phase I Injectable
Protocol within three (3) days of receipt by DTI. Serious adverse events shall
be designated using the current FDA definition of the term "serious". DTI shall
provide Fujisawa with listings of all non-serious adverse events occurring with
each Licensed Product during the Phase I Trial annually and at the completion of
the study. Completion of a study shall be defined, for purposes of this Section
4.5(b) only, as that period of time one (1) week following Fujisawa's approval
of the final study report.

     After launch of the Licensed Products, DTI shall be responsible for
reporting to Fujisawa all serious adverse events associated with the Licensed
Products of which DTI becomes aware, whether within or outside the Territory,
within twenty four (24) hours after DTI becomes aware of such serious adverse
event. DTI shall notify Fujisawa of any non-serious adverse events associated
with the Licensed Products within the Territory of which DTI becomes aware
within ten (10) days of DTI becoming aware of the non-serious adverse event.

     DTI shall report to Fujisawa all serious adverse events associated with the
Non-Injectable Products during both clinical development and following launch of
the Non-Injectable Products, both within and outside the Territory, within ten
(10) days of DTI becoming aware of such serious adverse event.

     DTI shall report both serious and non-serious adverse events on forms
agreed upon by the Parties. DTI shall notify the contact person designated by
Fujisawa by fax at (847) 317-1241 or telephone at (800) 727-7003, as may be
revised.

     4.6   Regulatory Actions; Product Recalls; Product Withdrawals. In the
event (i) any government authority issues a request, directive or order that any
Licensed Product be recalled or withdrawn; (ii) a court of competent
jurisdiction orders such recall or withdrawal; or (iii) Fujisawa reasonably
determines that any Licensed Product should be recalled or withdrawn for any
reason, Fujisawa shall take all appropriate corrective actions requested by any
such government authority. DTI shall fully cooperate with Fujisawa in connection
with any such recall or withdrawal. In the event that such recall or withdrawal
results from the breach of and/or failure to comply with any of DTI's
obligations, representations and/or warranties under this Agreement, DTI shall
be solely responsible for the expenses of such recall or withdrawal. In the
event the recall or withdrawal results from any other reason, Fujisawa shall be
responsible for the expenses of the recall or withdrawal. For purposes of this
Agreement, the expenses of any such recall or withdrawal shall be all out of
pocket expenses incurred by either Party relative to the notification, shipping,
disposal and return of the recalled or withdrawn Licensed Product.

                                       16

<PAGE>

5.       PAYMENTS AND ROYALTIES

         5.1 License Fees. Fujisawa shall pay to DTI a nonrefundable,
noncreditable license issue fee of * upon execution of this Agreement.

         5.2 Development Costs. Within thirty (30) days of the Effective Date,
Fujisawa shall pay to DTI the amount set forth on Exhibit C, which represents
the actual development expenses incurred by DTI for the development of the
Compound after January 1, 1999 and prior to the Effective Date. Fujisawa shall
also reimburse DTI for the actual costs incurred by DTI in completing the Phase
I Trial, a budget for which is attached as Exhibit E. Within thirty (30) days
following the dosing of the last patient in the Phase I Trial, Fujisawa shall
reimburse DTI for * of its estimated costs set forth in such budget. The
remaining * (as may be adjusted up or down based upon actual costs as determined
by JMC) shall be paid within thirty (30) days of the receipt by Fujisawa of a
Final Clinical Study Report meeting the guidelines of the ICH (International
Conference on Harmonization). Fujisawa shall be responsible for paying all
additional development costs for the Licensed Product in accordance with the
terms and conditions of this Agreement.

         5.3 Milestones. Subject to the terms and conditions of this Agreement,
Fujisawa shall pay to DTI the following noncreditable and nonrefundable amounts
within thirty (30) days of the first achievement, by a Licensed Product in the
United States, of the respective milestone event set forth below:

                    Milestone Event                                    Payment
--------------------------------------------------------------------  ---------

(1) Reissuance of U.S. Patent No. 5,310,731                               *

(2) Completion of First Phase I Trial                                     *

(3) Completion of First Phase II Trial for the Licensed Product           *

(4) First Submission of a NDA for PSVT                                    *

(5) First Submission of a NDA for AFIB/F                                  *

(6) First Regulatory Approval of a Licensed Product for PSVT              *

(7) First Regulatory Approval of a Licensed Product for AFIB/F            *

Each milestone shall be paid only once; provided, however, that milestones need
not be achieved by the same Licensed Product (e.g., it may contain the Compound
or a Back-up Compound, or it may be developed for PSVT rather than AFIB/F) in
order to trigger a payment obligation under this Section 5.3. Milestones (1) -
(3) above shall be deemed "achieved" as follows:

             (a) Milestone (1) "Reissuance of U.S. Patent No. 5,310,731":
Following Fujisawa's receipt of notice of the reissuance of U.S. Patent No.
5,310,731, Fujisawa shall have thirty (30) days

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       17

<PAGE>

within which to either (i) pay Milestone (1) and maintain this Agreement in full
force and effect or (ii) terminate the Agreement in its entirety, in its sole
discretion, pursuant to Section 11.4(c), in which case it shall not be
responsible for paying Milestone (1) or any other milestone payment or any other
monies under this Agreement.

            (b) Milestone (2) "Completion of First Phase I Trial": Once the last
patient in the first Phase I Trial has been dosed, DTI shall be deemed to have
"completed" such trial, and Fujisawa shall pay Milestone (2) within sixty (60)
days after the date upon which the last such patient was dosed. For purposes of
clarity, it is understood that once the last patient is dosed, Fujisawa shall be
responsible for making such milestone payment; however, in the event Fujisawa
terminates this Agreement prior to such last patient being dosed, Fujisawa shall
not owe Milestone (2), nor any other milestone or any other monies under this
Agreement.

            (c) Milestone (3) "Completion of First Phase II Trial": Within 30
days of the date upon which a "lock" is placed on the database for the first
Phase II Trial for the Licensed Product (regardless of whether such trial
involves PSVT or AFIB/F), Fujisawa will either (i) pay Milestone (3) and retain
this Agreement in full force and effect, or (ii) provide notice that it elects
to terminate the Agreement with respect to the particular Primary Indication
tested; provided, that in the event of Completion (as hereinafter defined) of
the first Phase II Trial for the remaining Primary Indication (or any other
indication, if occurring earlier), Fujisawa shall either (i) pay Milestone (3)
and retain this Agreement in full force and effect, or (ii) provide notice that
it elects to terminate this Agreement with respect to such remaining Primary
indication, subject to Section 11.5. For purposes of this Section 5.3(c),
"Completion of first Phase II Trial" for such remaining Primary Indication (or
other indication) shall mean occurrence of the 30/th/ day following the date
upon which a "lock" is placed on the database for such Phase II Trial. In the
event Fujisawa terminates this Agreement with respect to a particular Primary
Indication, it will not owe such milestone payment, or any other milestone
payment or other monies with respect to such terminated Primary Indication.

        5.4 Earned Royalties. Fujisawa shall pay DTI a running annual royalty on
aggregate, annual Net Sales of all Licensed Products in the Territory, according
to the following marginal rates:

            (a) For Net Sales of Licensed Products up to * of such annual Net
Sales; and

            (b) For the portion of Net Sales of Licensed Products in excess of *
 and not exceeding * of such annual Net Sales; and

            (c) For the portion of Net Sales of Licensed Products in excess of *
 of such annual Net Sales.

        5.5 Royalties to Fujisawa. If DTI (or its licensee or contractee) uses
or relies upon any Fujisawa Data (as described in Section 3.9) that is contained
in a Regulatory Approval application submitted by Fujisawa, in order to obtain
Regulatory Approval for either a Licensed Product outside the Territory, any
Non-Injectable Product or any product containing a compound from the Al Agonist
Library (hereafter, a "Fujisawa Data Product"), DTI shall pay to Fujisawa a

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       18

<PAGE>

running royalty on annual Net Sales (as such term is defined pursuant to this
Section 5.5) of such Fujisawa Data Product according to the following marginal
rates:

          (a) For Net Sales of such Fujisawa Data Product up to * of such annual
Net Sales;

          (b) For the portion of annual Net Sales of such Fujisawa Data Product
in excess of * and not exceeding * of such annual Net Sales;

          (c) For the portion of Net Sales of such Fujisawa Data Product in
excess of * of such annual Net Sales;

provided, however, in no event shall the total royalty payments by DTI exceed *
times the actual costs borne by Fujisawa for the study(ies) which generated the
specific Data that is contained in Fujisawa's application for Regulatory
Approval and which DTI (or its licensee or contractee) uses or relies upon to
obtain Regulatory Approval for the particular Fujisawa Data Product. For
purposes of this Section 5.5, the term "Net Sales" shall have the same meaning
as provided in Section 1.28; provided, that (i) the word "Fujisawa" shall be
replaced by the word "DTI" and (ii) the word "Licensed Product(s)" shall be
replaced by the word "Fujisawa Data Product(s)".

          5.6 Additional Royalties to DTI. In addition to the royalty owed on
Licensed Products under Section 5.4, if Fujisawa (or its permitted sublicensee)
uses or relies upon any DTI Data (as described in Section 3.9) that is contained
in a Regulatory Approval application submitted by DTI, in order to obtain
regulatory approval for a Licensed Product in the Territory (hereafter, a "DTI
Data Product"), Fujisawa shall pay to DTI an additional running royalty, on
annual Net Sales (as such term is defined pursuant to this Section 5.6) of such
DTI Data Product according to the following marginal rates:

          (a) For Net Sales of such DTI Data Product up to * of such annual Net
Sales;

          (b) For the portion of Net Sales of such DTI Data Product in excess of
* and not exceeding * of such annual Net Sales;

          (c) For the portion of Net Sales of such DTI Data Product in excess of
* of such annual Net Sales;

provided, however, in no event shall the total royalty payments by Fujisawa
exceed * times the actual costs borne by DTI for the study(ies) which generated
the specific Data that is contained in DTI's application for Regulatory Approval
and which Fujisawa (or its sublicensee) uses or relies upon to obtain Regulatory
Approval for the particular DTI Data Product. For purposes of this Section 5.6,
the term "Net Sales" shall have the same meaning as provided in Section 1.28;
provided, that the word "Licensed Product(s)" shall be replaced by the word "DTI
Data Product(s)". The Parties acknowledge and agree that Fujisawa shall not owe
DTI any additional royalties under this Section 5.6 for any Data generated in
the Phase I Trial.

          5.7 Royalty Term. Fujisawa's obligation to pay royalties under Section
5.4 shall continue on a product-by-product basis (i) in the U.S. until five (5)
years after the expiration, lapse or

--------------------------------------------------------------------------------
*  Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       19

<PAGE>

invalidation by a decision of a court or tribunal of competent jurisdiction from
which no appeal is or can be taken of the last remaining DTI Patent (including
any extension thereof) which contains a valid and unexpired claim covering the
composition of matter or method of use of the relevant Licensed Product in the
U.S. and (ii) in Canada until the fifth (5/th/) anniversary of the date of the
first commercial sale of Licensed Product(s) in Canada (the "Royalty Term"). For
purposes of this Agreement "valid and unexpired claim" shall mean a composition
of matter or method of use claim or equivalent thereof, of an issued and
unexpired DTI Patent (or corresponding patent application, provided that the
original application containing such claim has not been pending for more than
five years covering the relevant Licensed Product in such country, which (i) has
not been revoked or held unenforceable or invalid by a decision of a court or
other governmental agency of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal; or (ii) has not been abandoned, disclaimed,
denied or admitted to be invalid or unenforceable through reissue of disclaimer
or otherwise.

     5.8  Withholding Taxes. Any tax paid or required to be withheld by a Party
on account of royalties payable to the other Party under this Agreement shall be
deducted from the amount of royalties otherwise due. The withholding Party shall
secure and send to the other Party written proof of any such taxes withheld and
paid by the withholding Party or its sublicensees for the benefit of the other
Party. The withholding Party shall reasonably assist the other Party in claiming
exemption from such deductions or withholdings under any double taxation or
similar agreement or treaty from time to time in force.

     5.9  Blocked Currency. In each country where the local currency is blocked
and cannot be removed from the country, at the election of the Party paying
royalties, royalties accrued in that country shall be paid to the other Party in
the country in local currency by deposit in a local bank designated by the other
Party.

     5.10 Royalty Payments and Reports. Beginning with the first commercial sale
of a Licensed Product, royalties shall accrue on Fujisawa's fiscal quarter
basis. The royalty-paying Party shall pay all amounts owed within forty-five
(45) days following the end of the relevant calendar quarter. Each royalty
payment shall be accompanied by a report summarizing the number, description,
and aggregate sales of Licensed Products made and the royalty payable thereon
according to Sections 5.4, 5.5, and 5.6 respectively, including a description of
any offsets or credits deducted from such sales, on a product-by-product and
country-by-country basis during the relevant three-month period. For any given
royalty period, the royalty-paying Party shall pay the royalty at the rate
specified in Section 5.4, 5.5, or 5.6 applicable to the then current
year-to-date Net Sales level. Each statement provided at the end of the fourth
quarter of each year shall contain a reconciliation of actual royalty payments
made during that year and the amount actually owed for such year according to
that year's Net Sales level, and the resulting amount, if any, shall be paid at
the time of such fourth quarter statement, in accordance with the terms of this
Section 5.10. The royalty-paying Party may credit any amounts paid in excess of
the amount actually owed against future quarterly royalty payments.

     5.11 Currency; Exchange Rate. Subject to Section 5.9, all amounts paid
under this Agreement shall be paid in U.S. dollars to either Party by wire
transfer to a financial institution to be designated by the Party to whom
payment is owed. The royalty on sales by either Party or

                                       20

<PAGE>

their respective sublicensee(s) of Licensed Products sold in a currency other
than United States Dollars shall be converted into United States Dollars using
the selling rate of exchange for the currency of the country from which the
royalties are payable as published by the Wall Street Journal, New York, N.Y.,
U.S.A., for the last business day of the quarterly period for which the
royalties are due.

     5.12 Accounting. Each Party agrees to keep and maintain such records, using
generally accepted accounting principles (GAAP) consistently applied, as it
normally generates in the ordinary course of its business for a period of three
(3) years showing the sale, use, and other disposition of products sold or
otherwise disposed of under the license herein granted. Such records shall be
kept in sufficient detail to enable the royalties payable hereunder by either
Party to be determined. Each Party further agrees to permit its books and
records to be examined by an independent certified public accountant selected by
the other Party, at ordinary business hours with reasonable prior notice and not
more than once per year, to the extent necessary to verify reports and payments
provided for in this Agreement. Following completion of the Phase I Trial,
Fujisawa may audit DTI's books with respect to any costs incurred by DTI and
reimbursed by Fujisawa, including, without limitation, pre-clinical, and Phase I
Trial expenses, and those incurred and reimbursed under Section 2.7, along with
such Phase I Trial. No copies of either Party's records shall be copied or
retained by such examiner. Such examination is to be made under appropriate
confidentiality restrictions, at the expense of the auditing Party, except in
the event that the results of the audit reveal an underreporting of royalties
due to the auditing Party of * or more in any year, then the
audit costs shall be paid by the audited Party.

6.   MANUFACTURING

     6.1 General. DTI will be responsible for obtaining sufficient quantities of
Licensed Products necessary for it to conduct the Phase I Trial. Fujisawa will
be responsible for identifying a suitable manufacturer, developing commercial
manufacturing processes and supplying subsequent clinical and commercial
quantities of Licensed Products for distribution and sale in the Territory. DTI
will cooperate with Fujisawa in connection with such third party manufacturer.

     6.2 Quality Assurance. Fujisawa shall have day to day responsibility for
commercial manufacturing and formulation issues related to product safety and
regulatory compliance. All Licensed Products used in clinical and commercial
supplies will be manufactured, tested, and released according to current cGMP's
and all other applicable law and regulatory requirements of the country in which
such Licensed Products are to be used or distributed and sold. Both parties will
be responsible for maintaining its facilities and procedures, including those of
Third Parties, in material compliance with cGMP's and applicable laws and
regulatory requirements. The Parties will promptly notify each other in advance,
if known, of any governmental regulatory inspections and, within twenty four
(24) hours of any such inspection, shall provide the other Party with the
results of any governmental regulatory inspections or other governmental
regulatory action concerning the facilities or other manufacturing or
formulation issues, copies of all Form FD 483's (or their non-U.S. equivalents)
and compliance related documentation, including all actions taken by a Party in
response thereto

                                       21

<PAGE>

or as a result thereof. Any expenses incurred in improving compliance with
applicable regulatory requirements or responding to Form FD 483's (or their
non-U.S. equivalents) or other compliance-related documentation will be the full
responsibility of Fujisawa.

7. REPRESENTATIONS AND WARRANTIES; DISCLAIMERS

   7.1 Representations and Warranties.

       (a) Each Party hereby represents and warrants to the other that this
Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms, and that the execution, delivery and
performance of this Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a Party
or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.
Each Party expressly represents and warrants that it has full right, power and
authority to execute and deliver this Agreement and to perform their respective
obligations contemplated hereby.

       (b) DTI hereby represents and warrants to Fujisawa that:

           (i)   No consent of any Third Party is required for DTI to grant the
exclusive license to Fujisawa under Section 2.1, to enter into this Agreement
and/or to perform its obligations hereunder.

           (ii)  DTI owns, or controls (with the right to grant sublicenses
consistent with those granted Fujisawa hereunder) the DTI Patents and DTI
Know-How.

           (iii) DTI has not, and during the term of the Agreement will not,
grant any right to a Third Party under the DTI Patents and DTI Know-How in the
Field that would conflict with any of the rights granted to Fujisawa under this
Agreement.

           (iv)  DTI has not to its knowledge received any communication or
claim from, or by any Third Party, nor is otherwise aware of, any issue relative
to the validity, enforceability or infringement of any of the DTI Patents and/or
that the practice of the inventions claimed in the DTI Patents and/or comprising
the DTI Know-How infringe the rights of any Third Party.

           (v)   To the best of DTI's knowledge, there is no prior art that has
not been cited by DTI to the PTO which would invalidate the DTI Patents. The DTI
Patents have not been obtained through any misrepresentation that would affect
or destroy the validity and/or enforceability of the DTI Patents.

           (vi)  There are no claims currently asserted or, to the best of DTI's
knowledge, threatened by any Third Party involving, questioning and/or relative
to: (i) Fujisawa's right to use and/or receive from DTI the exclusive license
under this Agreement; and/or (ii) DTI's ability to enter into this Agreement and
perform its obligations hereunder.

                                       22

<PAGE>

          (vii)  As of the Effective Date, it has not received any notices that
the manufacture, use, sale or importation of the Compound or the Back-up
Compounds infringe the intellectual property rights of any Third Party.

          (viii) The U.S. Patent No. 5,310,731 is the subject of a reissue
application to correct a defect with respect to certain claims in such U.S.
Patent. Except with respect to this defect and to the best of DTI's knowledge,
the DTI Patents are valid and enforceable, and there has been no lapse in any of
rights provided by the DTI Patents.

          (ix)   DTI represents and warrants that to the best of its knowledge
DTI has disclosed to Fujisawa all material information in DTI's possession or
control concerning side effects, injury, toxicity or sensitivity reaction and
incidents associated with the use of Licensed Products obtained from any
non-clinical studies.

          (x)    DTI has conducted all pre-clinical studies for the Compound,
the Back-up Compounds and the Licensed Products, if any (collectively "DTI's
Pre-Clinical Studies") in substantial compliance with Good Laboratory Practices
and all applicable Federal, state and local laws, rules, regulations and
guidelines governing the conduct of pre-clinical studies. To the best of DTI's
knowledge, neither DTI nor any of the investigators, institutions, laboratories,
clinical research organizations or other individuals or entities participating
in DTI's Pre-Clinical Studies have been or are "debarred" as such term is used
in Section 335a of the United States Code. Any and all necessary financial
disclosures have been obtained in accordance with 21 CFR Part 54, from the
investigators and/or institutions participating in DTI's Clinical Studies, to
the extent applicable.

     7.2 Warranty Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET
FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR
WARRANTY, EITHER EXPRESS OR IMPLIED WITH RESPECT TO THE COMPOUND, THE BACK-UP
COMPOUNDS OR THE LICENSED PRODUCTS. EXCEPT AS PROVIDED ABOVE, THERE ARE NO
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR THAT THE USE OF THE LICENSED PRODUCT(S) WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS, OR ANY OTHER EXPRESS OR
IMPLIED WARRANTIES.

     7.3 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT,
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, INCURRED BY EITHER PARTY AND
ARISING FROM PERFORMANCE OR NONPERFORMANCE UNDER THIS AGREEMENT, WHETHER BASED
ON AN ACTION IN CONTRACT OR TORT - OR BASED ON A WARRANTY.

8.   INDEMNITY AND INSURANCE

     8.1 Indemnification by Fujisawa. Fujisawa hereby agrees to indemnify,
defend and hold harmless DTI and its agents and employees from and against any
and all Third Party suits, claims, actions, demands, liabilities, expenses
and/or loss, including reasonable attorneys' fees and costs (such Third Party
suits, claims, actions, demands, liabilities, expenses and/or loss,

                                       23

<PAGE>

including reasonable attorneys' fees and costs shall be referred to herein as
"Losses") resulting from (a) Fujisawa's breach of any of its obligations,
agreements, covenants, representations and/or warranties hereunder; (b) any use
of DTI's Data (except where such Data is either fraudulent or otherwise does not
meet the requirements of applicable rules, regulations and/or law) and/or (c)
the manufacture, use, handling, storage, sale or other disposition of Licensed
Products by Fujisawa, its agents, representatives, consultants or sublicensees
except to the extent such Losses result from (i) the negligence or wrongdoing of
DTI, its agents, representatives, consultants or employees, or (ii) from the
actions or inactions of DTI, its agents, representatives, consultants or
employees for which DTI is obligated to indemnify Fujisawa pursuant to Section
8.2.

     8.2   Indemnification by DTI. DTI hereby agrees to indemnify, defend and
hold harmless Fujisawa and its agents and employees from and against any and all
Losses resulting from (a) DTI's breach of any of its obligations, agreements,
covenants, representations and warranties hereunder; (b) any use of Fujisawa's
Data (except where such Data is either fraudulent or otherwise does not meet the
requirements of applicable rules, regulations and/or law); and/or (c) any use of
Data generated by or on behalf of DTI in the Phase I Trial which is either
fraudulent or otherwise does not meet the requirements of applicable rules,
regulations and/or law; except to the extent such Losses result from (i) the
negligence or wrongdoing of Fujisawa, its agents, representatives, consultants
or employees, or (ii) the actions or inactions of Fujisawa, its agents,
representatives, consultants or employees for which Fujisawa is obligated to
indemnify DTI pursuant to Section 8.1.

     8.3   Indemnification Procedure. If a Party (in this context, the
"Indemnified Party" seeks indemnification under the applicable provision of this
Section 8, the Indemnified Party shall promptly notify the other Party (in this
context, the "Indemnifying Party") of its claim for indemnification
("Indemnified Claim"), but in no event more than ten (10) business days after
the Indemnified Party has been served with legal process or otherwise received
notice of the commencement of any action by a third party; provided, however,
that the right of the Indemnified Party to indemnification shall be reduced in
the event of its failure to give timely notice only to the extent the
Indemnifying Party is prejudiced thereby. The Indemnified Party shall defend the
Indemnified Claim. The Indemnified Party may retain separate co-counsel at its
sole cost and expense and participate in the defense of the Indemnified Claim.
The Indemnified Party shall fully cooperate with the Indemnifying Party's
defense of any Indemnified Claim, including without limitation providing any and
all required knowledge and documents and access to its employees.

     8.4   Insurance. In addition to the foregoing, both Parties shall obtain
appropriate insurance in accordance with standard commercial practices to cover
their respective indemnities granted in Sections 8.1 and 8.2. Each Party agrees
to provide evidence of such coverage if requested by the other Party.

9.   PROTECTION OF PATENTS; CLAIMS OF INFRINGEMENT

     9.1   Ownership of Intellectual Property. Each Party shall solely own
inventions made within and outside of the United States by that Party's
employees or agents or consultants

                                       24

<PAGE>

in the course of performing any work under this Agreement. Inventions made
jointly by employees, agents or consultants of DTI and Fujisawa shall be owned
jointly by DTI and Fujisawa, with each party retaining an undivided one-half
interest in such jointly-developed inventions pursuant to Section 9.5. The law
of ownership of inventions of the United States shall apply to any patents filed
or issued outside the United States claiming inventions of the Parties. For all
inventions under this Section 9.1, the Parties shall provide reasonable
assistance to each other in perfecting title to such inventions.

     9.2   Infringement of DTI Patents.

           (a)  Each Party shall promptly notify the other in writing of any
alleged or threatened infringement of any DTI Patents in the U.S. Both Parties
shall use their commercially reasonable efforts in cooperating with each other
to terminate such infringement.

           (b)  Subject to Section 9.2(e), Fujisawa shall have the first right
to bring and control any action or proceeding with respect to infringement of a
DTI Patent in the U.S., to the extent such infringement involves a product which
is an Injectable Product that is competitive with a Licensed Product, at its own
expense and by counsel of its own choice. DTI shall have the right, at its own
expense, to be represented in any such action involving a DTI Patent. If
Fujisawa fails to bring an action or proceeding with respect to such
infringement within: (b) (i) ninety (90) days following the notice of alleged
infringement or (ii) ten (10) days before the time limit, if any, set forth in
the appropriate laws and regulations for the filing of such actions, whichever
comes first, it shall notify DTI and DTI shall have the right to bring and
control any such action at its own expense and by counsel of its own choice,
subject to Section 9.2(e). Prior to providing such notification to DTI, Fujisawa
shall take any action (or cause to be taken any action) necessary to reasonably
ensure that the rights of DTI under any such action are not prejudiced,
including but not limited to filing a responsive pleading or obtaining an
extension of time to do so. Fujisawa shall have the right, at its own expense,
to be represented in any such action by counsel of its own choice.

           (c)  DTI (or its licensee) shall have the first right to bring and
control any action or proceeding with respect to infringement of a DTI Patent in
the U.S., to the extent such infringement involves a product which is a
Non-Injectable Product, or is an Injectable Product, but is not competitive with
a Licensed Product, at its own expense and by counsel of its own choice.
Fujisawa shall have the right, at its own expense, to be represented in any such
action by counsel of its own choice, where such action involves an Injectable
Product. If DTI (or its licensee) determines not to pursue an infringement
action under this Section 9.2, it shall promptly notify Fujisawa, and Fujisawa
shall have the right to bring and control any such action at its own expense and
by counsel of its own choice, subject to Section 9.2(e). Prior to providing such
notification to Fujisawa, DTI shall take any action (or cause to be taken any
action) necessary to reasonably ensure that the rights of Fujisawa under any
such action are not prejudiced, including but not limited to filing a responsive
pleading or obtaining an extension of time to do so. Fujisawa may elect, but
shall not be obligated, to bring, at its own expense, any such action DTI (or
its sublicensee) elects not to bring. DTI (and its sublicensee) shall have the
right, at its own expense, to be represented in any such action involving a DTI
Patent which Fujisawa brings under this Section 9.2(c).

                                       25

<PAGE>

          (d)  In the event a Party brings an infringement action against a
Third Party, the other Party shall cooperate fully, including, where necessary,
joining the action as a Party plaintiff. Neither Party shall have the right to
settle any patent infringement litigation under this Section 9.2 without the
prior written consent of such other Party. If there is no agreement between the
Parties as to any proposed settlement, then the dispute shall be resolved
pursuant to Article 13.

          (e)  Any recovery realized as a result of such litigation, after
reimbursement of any litigation expenses for Fujisawa and DTI, shall belong to
the Party bringing the litigation; provided, however, if Fujisawa recovers
damages as a result of such litigation that are attributable to lost sales of
Licensed Products, such amounts shall be treated as if they were Net Sales and
Fujisawa shall pay to DTI the royalties due under Section 5.4 as if such amounts
were Net Sales of such Licensed Products.

     9.3  Defense and Settlement of Third Party Claims of Patent Infringement.

          (a)  General. If a Third Party asserts against Fujisawa or DTI that a
patent, trademark or other intangible right owned by it is infringed by the
manufacture, use or sale of any Licensed Product manufactured or sold in the
Territory by Fujisawa or its sublicensee, each Party will promptly notify the
other in writing and Fujisawa shall be solely responsible for (a) defending such
action, subject to the requirements of this Section 9.3, and subject to Section
9.3(b) Fujisawa shall pay any and all costs, expenses (including attorneys' fees
and costs) fees, license fees, payments, royalties and expenses in connection
with such defense and/or settlement.

          (b)  Royalty Offset. Fujisawa may credit against the royalty payments
owed to DTI under Section 5.4 for sales of Licensed Products * of all of its
costs, expenses, fees (including attorneys' fees and costs), license fees,
payments, royalties and any other amounts expended to defend or settle such
action and/or obtain a license; provided, that the maximum amount of credit that
Fujisawa may apply against such royalty payments in any given quarter shall not
exceed * of the royalty payment owed in such quarter (the "*"). Any amounts in
excess of the * Threshold for any prior quarter may be credited against
subsequent quarterly royalty payments owed to DTI, subject to the * Threshold
limitation for any such subsequent quarter, until the total amount has been
credited.

          (c)  Settlement with a Third Party. The entity that controls the
defense of a given claim with respect to a Licensed Product shall also have the
right to control settlement of such claim; provided, however, that no settlement
shall be entered into without the prior written consent of the other Party. If
there is no agreement between the Parties as to any proposed settlement, then
the dispute shall be resolved pursuant to Article 13.

     9.4  Prosecution and Maintenance of DTI Patents. DTI shall be responsible
for obtaining the re-issuance of U.S. Patent No. 5,310,731 and maintaining all
DTI Patents. DTI shall keep Fujisawa informed as to the status of the reissuance
and shall promptly provide copies of any and all documentation and
correspondence to and from the PTO. Fujisawa shall reimburse DTI for all of its
reasonable expenses incurred after the Effective Date for prosecuting and
maintaining the DTI Patents (other than costs in connection with the reissuance)
in the United States until such time as DTI commercializes a Non-Injectable
Product in the United States, at which point

--------------------------------------------------------------------------------

 *  Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.

--------------------------------------------------------------------------------

                                       26

<PAGE>

Fujisawa shall be responsible for reimbursing DTI for *of its expenses for
maintaining DTI Patents. DTI shall notify Fujisawa if it intends to abandon any
DTI Patent or other patent covering the Licensed Product at least sixty (60)
days prior to any relevant deadline. Fujisawa shall have the right, at its own
expense and under its own name, to file and assume prosecution and maintenance
of any patent or patent application abandoned by DTI, and all rights under such
abandoned DTI Patent or other patent shall revert or be assigned by DTI to
Fujisawa.

     9.5    Prosecution and Maintenance of Joint Patents. For all patents
claiming jointly owned inventions ("Jointly Owned Patents"), the Parties shall
work together to develop a reasonable patent strategy appropriate for the
technology at issue. DTI shall have the first right, but not the obligation, to
prosecute and maintain any Jointly Owned Patents. DTI shall permit Fujisawa to
review and comment on any documents filed with the relevant patent authorities
in the Territory with respect to any Jointly Owned Patents. Fujisawa shall
reimburse DTI for fifty percent (50%) of its expenses in prosecuting and
maintaining Jointly Owned Patents in the Territory; provided, however, that
Fujisawa may elect to forego its ownership interest in such Jointly Owned Patent
application during the sixty (60) day period following the filing of such
application, in which case it shall not reimburse DTI and shall assign over its
interest. If DTI elects not to prosecute a Jointly Owned Patent, or to abandon
any Jointly Owned Patent, it shall provide sixty (60) days written notice to
Fujisawa prior to any relevant deadline and Fujisawa shall have the right, but
not the obligation, to prosecute and maintain such patent at Fujisawa's expense,
and under its own name. DTI shall have the right to grant licenses under any
Jointly Owned Patents to any Third Party without the consent of Fujisawa,
subject to the license in Section 2.1. Fujisawa shall have the right to grant
licenses under any Jointly Owned Patents (i) to any Third Party to make, have
made, use, import, export, offer for sale and sell Licensed Products without the
consent of DTI, but only so long as this Agreement is in effect, and only in
connection with a sublicense permitted under Section 2.2 and (ii) to any Third
Party for any other use, without the consent of DTI.

10.  CONFIDENTIALITY

     10.1   Information. Each Party shall keep all information received from the
other Party (the "Information") confidential and shall not disclose nor use the
Information without the other Party's written consent except to the extent
contemplated by this Agreement. This restriction shall not, however, prevent
disclosure of the Information if and to the extent that disclosure is required
by law, provided that the disclosing Party informs the other Party without delay
of any such requirement, in order to allow such other Party to object to such
disclosure and to seek an appropriate protective order or similar protection
prior to disclosure.

     10.2   Exceptions. The above obligations shall not apply or shall cease to
apply to Information which:

            (a)  is now, or hereafter becomes, through no act or failure to act
on the part of the receiving Party, generally known or available to the public;

            (b)  is known by the receiving Party at the time of receiving such
information, as evidenced by its written records;

                                       27

<PAGE>

            (c)  is hereafter furnished to the receiving Party by a third party,
as a matter of right and without restriction on disclosure;

            (d)  is independently developed by the receiving Party without any
breach of this Section 10 as is evidenced by written records; or

            (e)  is the subject of a written permission to disclose provided by
the disclosing Party.

     10.3   Permitted Disclosures. Information may be disclosed for the purpose
of filing, prosecuting and maintaining the DTI Patents, for obtaining Regulatory
Approvals, and to employees, agents, consultants, Third Party contract
manufacturer, sublicensees or suppliers of the recipient Party, but only to the
extent required to accomplish the purposes of this Agreement and only if such
individuals are required by law, contract or otherwise not to use or disclose
such information except as permitted by this Agreement. Each Party will use at
least the same standard of care as it uses to protect proprietary or
confidential information of its own to ensure that such employees, agents,
consultants, sublicensees or suppliers do not disclose or make any unauthorized
use of the Information.

     10.4   Disclosure of Agreement; Press Releases. Except as required by law,
neither DTI nor Fujisawa shall release to any Third Party or publish in any way
any non-public information with respect to the terms of this Agreement without
the prior written consent of the other; provided; however that either Party may
disclose the terms of this Agreement to the extent required to comply with
applicable laws, including without limitation the rules and regulations
promulgated by the Securities and Exchange Commission. Notwithstanding any other
provision of this Agreement, each Party may disclose the terms of this Agreement
to lenders, investment bankers, financial advisors and other financial
institutions of its choice solely for purposes of financing the business
operations of such Party, or to potential investors in or acquirors of such
Party either (i) upon the written consent of the other Party or (ii) if the
disclosing Party obtains a signed confidentiality agreement with such intended
recipient with respect to such information, upon terms substantially similar to
those contained in this Section. Notwithstanding the foregoing, promptly
following execution of this Agreement the Parties will issue mutually agreed
upon press release(s). Any future press releases or other public disclosures
cannot be made by one Party without the prior written consent of the other
Party, with the understanding that Fujisawa will have sole decision making
authority to the extent any such press release covers the Licensed Product,
except to the extent required by law and except when the information has already
been publicly disclosed in a prior press release or filing required under the
Securities and Exchange Act.

11.  TERM AND TERMINATION

     11.1   Term. This Agreement shall commence on the Effective Date and expire
at the end of the Royalty Term under Section 5.7. Upon the expiration (but not
the earlier termination) of the Royalty Term, the licenses granted hereunder to
Fujisawa shall convert to non-exclusive, fully paid and royalty-free licenses.

                                       28

<PAGE>

     11.2 Early Termination for Material Breach. If either Party commits a
material breach of this Agreement and such breach is not cured within ninety
(90) days after written notice thereof by the non-breaching Party, or if such
breach is incapable of cure during the applicable notice period, the breaching
Party fails to make good faith efforts to cure such breach, the non-breaching
Party may terminate this Agreement upon expiration of the notice period.
Notwithstanding the foregoing, any termination by DTI under this Section 11.2
for a material breach by Fujisawa shall only be effective as to the particular
Licensed Product at issue, and for the particular indication for which it was
under development or being sold, except for material breach of Sections 2.1,
2.6, 3.8(a)(iii), 3.9, 5.3, 5.4, 5.6, and 10.1, in which case the entire
Agreement may be terminated by DTI.

     11.3 Termination for Bankruptcy. All rights and licenses granted under or
pursuant to this Agreement by DTI to Fujisawa are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights
to "Intellectual Property" as defined under Section 101(56) of the Bankruptcy
Code. The Parties agree that Fujisawa, as a licensee of such rights and
licenses, shall retain and may fully exercise all of its rights and elections
under the Bankruptcy Code. The parties further agree that, in the event that any
proceeding shall be instituted by or against DTI seeking to adjudicate it as
bankrupt or insolvent, or seeking liquidation, winding up, reorganization,
arrangement, adjustment, protection, relief or composition of it or its debts
under any law relating to bankruptcy, insolvency or reorganization or relief of
debtors, or seeking an entry of an order for relief or the appointment of a
receiver, trustee or other similar official for it or any substantial part of
its property or it shall take any action to authorize any of the foregoing
actions (each a "Proceeding"), Fujisawa shall have the right to retain and
enforce its rights under this Agreement to the full extent under applicable law,
including without limitation, any rights under Section 365(n) of the Bankruptcy
Code.

     11.4 Early Termination by Fujisawa.

          (a)  Termination for Safety. Subject to Section 11.6, Fujisawa may
terminate this Agreement in whole or in part (i.e., with respect to a particular
Licensed Product and/or indication) at any time upon thirty (30) days prior
written notice if: Fujisawa determines that there are safety concerns regarding
the Licensed Products such that no Licensed Product could reasonably be
developed that would meet Fujisawa's standards for product safety, so long as
such determination is made in good faith and that Fujisawa applies the same
standards to evaluate the safety of Licensed Products as it typically and
customarily would apply for the safety evaluation of other products, including
products derived from its own research and development efforts, at similar
stages of development. In the event Fujisawa terminates under this Section
11.4(a), it would not owe any milestone payment that became due during the
thirty (30) day notice period, or any other monies hereunder with respect to the
terminated Licensed Product and/or indication, except for Milestone (2) under
Section 5.3(b) in accordance with the terms thereof, where such termination
occurred after the dosing of the last patient in the Phase I Trial.

          (b)  Termination for Other Scientific Reasons. Subject to Section
11.6, Fujisawa may terminate this Agreement in whole or in part (i.e., with
respect to a particular Licensed Product and/or indication) upon ninety (90)
days prior written notice if: it determines

                                       29

<PAGE>

not to continue further research and development for reasons concerning
efficacy, dosing regimen or formulation, so long as such determination is made
in good faith and that Fujisawa applies the same standards to evaluate such
factors with respect to Licensed Products as it typically and customarily would
apply for the similar evaluation of other products, including products derived
from its own research and development efforts, at similar stages of development.
In the event Fujisawa terminates under this Section 11.4(b), it would not owe
any milestone payment that became due during the ninety (90) day notice period,
or any other monies hereunder with respect to the terminated Licensed Product
and/or indication, except for Milestone (2) under Section 5.3(b) in accordance
with the terms thereof, where such termination occurred after the dosing of the
last patient in the Phase I Trial.

          (c)  Termination for Non-Issuance of Valid DTI Patent. Fujisawa may
terminate this Agreement in its entirety for non-issuance of the DTI Patent
pursuant to Section 5.3(a).

          (d)  Termination for Other Patent Issues. Fujisawa may terminate this
Agreement in its entirety upon thirty (30) days prior written notice if it
determines in good faith after receiving an opinion of outside patent counsel,
that the manufacture, use, distribution or sale of any of the Licensed Products
would likely infringe any patent that issues in the United States and/or Canada
after the Effective Date.

          (e)  Termination for Convenience. After two (2) years from the
Effective Date, Fujisawa may at its sole discretion elect to terminate this
Agreement in its entirety for any reason at any time upon thirty (30) days prior
written notice. In the event Fujisawa terminates under this Section 11.4(e), it
would not owe any milestone payment that became due during the thirty (30) day
notice period or any other monies hereunder, except for Milestone (2) under
Section 5.3(b) in accordance with the terms thereof, where such termination
occurred after the dosing of the last patient in the Phase I Trial.

          (f)  Obligations During Termination Notice Period. If Fujisawa
terminates this Agreement pursuant to Section 11.4(a), (b) or (c), it shall not
be obligated, during the applicable termination notice period in Section 11.4
(a), (b) or (c), to perform its obligations under Sections 3.5, 3.7, 4.1 and 4.2
of this Agreement.

     11.5 Termination of Entire Agreement. Notwithstanding Section 3.5(b), 3.6,
4.2(a), 5.3(c), 11.4(a), or 11.4(b), in the event Fujisawa's rights to both
Primary Indications are terminated (i) by DTI pursuant to Section 3.5(b), 4.2(a)
or 11.2 or (ii) by Fujisawa pursuant to Section 3.6, 5.3(c) or 11.4(a) or
11.4(b), and in the further event that Fujisawa has not commenced development
with respect to the Licensed Product for any other indication in the Field at
the time of such termination, then DTI shall also have the right to terminate
this Agreement in its entirety, in which case Fujisawa's rights, to the extent
they exist, to make, have made, use, sell, offer for sale, import and export
Licensed Products for all other indications in the Field shall terminate and
Section 11.7 shall apply.

     11.6 Effect of Partial Termination. In the event there is any termination
under this Agreement (including without limitation any termination provided for
under Section 3.5(b), 3.6, 4.2(a), 5.3(c), 11.2, 11.4(a) or 11.4(b), where such
termination is only effective as to a particular

                                       30

<PAGE>

Licensed Product and/or certain indication for such Licensed Product, the
Parties acknowledge and agree that with respect to any other Licensed Product
and/or indication licensed at such time to Fujisawa under this Agreement, the
terms and conditions of this Agreement shall remain in full force and effect,
subject to Section 11.5.

     11.7 Effect of Early Termination.

          (a)  In the event Fujisawa terminates this Agreement pursuant to
Section 11.4(a) or 11.4(b) and the Phase I Trial is not concluded as of the
effective date of such termination, Fujisawa shall be obligated to reimburse DTI
under Section 5.2 only for the costs of such Phase I Trial incurred up to the
effective date of such termination; provided, however, that Fujisawa shall
nonetheless reimburse DTI for all costs owed to a Third Party which could not be
canceled by DTI and reasonably incurred by DTI through the completion of the
Phase I Trial. DTI shall use reasonable commercial efforts to negotiate a
cancellation of such costs.

          (b)  In the event that Fujisawa terminates this Agreement pursuant to
Section 11.4(a), (b), (c), (d) or (e), or either Party terminates for material
breach under Section 11.2, the following shall apply:

               (i)   all licenses to Fujisawa with respect to Licensed Products
shall terminate (or, where partially terminated, the Licensed Product and/or
indication at issue);

               (ii)  except in the event Fujisawa terminates for DTI's material
breach under Section 11.2, Fujisawa hereby grants to DTI a royalty-free (Except
for those royalties provided in Section 5.5), non-exclusive license under the
Fujisawa Technology to make, have made, use, sell, have sold, export and import
Licensed Products worldwide, in the Field (or, where partially terminated, the
Licensed Product and/or indication at issue);

               (iii) Fujisawa and DTI shall cooperate to ensure that the
development and commercialization of Licensed Products in the Territory
continues with a minimum of delay resulting from the transfer of rights back to
DTI. Fujisawa shall promptly transfer to DTI at DTI's written request all
Fujisawa Technology and assign all INDs, applications for Regulatory Approval
and Regulatory Approvals, or their Canadian equivalents (as applicable) as it
may hold with respect to such Licensed Product(s) in the Territory, and any
information as Fujisawa may possess which is useful to gain Regulatory Approval
for and to commercialize such Licensed Product(s) in such country. In the event
such assignment is not permitted by law, Fujisawa will cooperate in the
cancellation of such government approval, clearance, registration or permit
standing in its name and the reissuance of such government approval, clearance,
registration or permit to DTI or its designee. Such transfer shall be without
cost to DTI, provided however that DTI shall pay any governmental filing or
transfer fees that may be required;

               (iv)  to the extent it has the right to do so, Fujisawa shall
grant to DTI a sublicense under any Third Party licenses to which Fujisawa has
rights, to the extent that such rights are necessary or useful to make, have
made, use, import, offer for sale and sell such Licensed Product. DTI shall
thereafter assume the cost of maintaining its proportionate share of such
sublicenses and shall perform such obligations of Fujisawa under such license
agreement as are applicable to the relevant Licensed Product. To the extent such
Third Party license is no

                                       31

<PAGE>

longer applicable or useful to Fujisawa, Fujisawa shall assign to DTI all of its
rights and obligations, rather than grant a sublicense under, such license
agreement; and

               (v)  Fujisawa shall take all such other reasonable actions and
execute such other instruments, assignments and documents as may be necessary to
effect the transfer of rights hereunder.

Notwithstanding the foregoing, it is expressly understood and agreed that the
foregoing provisions regarding license terminations, transfer of data,
assignment of regulatory filings and the like shall only be effective as to the
particular Licensed Product at issue, and for the particular indication for
which it was under development or being sold, where this Agreement is terminated
in part as provided for in this Agreement.

          (c)  At the time of any early termination, if Fujisawa has already
commenced manufacturing of the Licensed Product as to which its rights have been
terminated. Fujisawa shall continue to provide for manufacture of the Licensed
Products to the extent necessary to meet expected market demand, from the
effective date of such termination until such time as DTI is able to secure an
alternative commercial manufacturing source, as requested by DTI; provided, that
Fujisawa shall in no event be required to continue to manufacture for more than
eighteen (18) months after the effective date of such termination or in
quantities in excess of those being produced at the time of such termination. As
of the effective date of such termination, all Third Party manufacturing
contracts for manufacture of Licensed Products shall be assigned to DTI, to the
extent that Fujisawa has the right to do so, and DTI will assume any and all of
Fujisawa's obligations under any of such contracts. Except in the event of
Fujisawa's termination of this Agreement for DTI's material breach under Section
11.2, in addition, upon DTI's request, Fujisawa shall provide such technical
assistance and know-how licenses on a royalty-free basis as may reasonably be
requested to transfer such technology as is needed by DTI to commence or provide
for commercial manufacture of Licensed Product. Fujisawa shall provide such
technical assistance to DTI for a period of sixty (60) days following the
effective date of termination. Fujisawa shall only be obligated to provide such
assistance if it is promptly reimbursed for any and all out-of-pocket expenses
incurred in rendering such assistance and at a reasonable hourly rate, mutually
agreed to by the parties, for the work of the employees providing such
assistance. In the event Fujisawa is unable to assign to DTI any such
manufacturing contracts, then Fujisawa shall continue to have the Licensed
Product manufactured for a period in no event to exceed eighteen (18) months
from the effective date of termination so as to enable DTI to qualify a new
Third Party contract manufacturer. If such Third Party is qualified prior to the
end of such eighteen (18) month period, then Fujisawa's obligation to have the
Licensed Product manufactured shall cease upon the date such Third Party is so
qualified. Notwithstanding anything to the contrary contained in Section 8.1 or
8.2, during such period in which Fujisawa is continuing to have the Licensed
Product manufactured after termination of this Agreement, DTI agrees to
indemnify, defend and hold harmless, Fujisawa and its agents representatives,
consultants and employees from and against any and all Losses resulting from the
manufacture, use, handling, storage, sale or other disposition of Licensed
Products by DTI, its agents representatives, consultants or employees, and/or
the third party contract manufacturer, except to the extent such Losses result
from the negligence or wrongdoing of Fujisawa, its agents representatives,
consultants or employees (excluding any Third Party manufacturing the

                                       32

<PAGE>

Licensed Product after the effective date of such termination) in accordance
with Section 8.3. If any technology needed by DTI to commence or provide for
commercial manufacture of Licensed Product is covered by one or more patents
owned or controlled by Fujisawa, DTI shall receive a fully paid-up,
royalty-free, non-exclusive worldwide license to practice any and all such
patents for the purposes contemplated in this Section 11.7, with the right to
grant sublicenses.

     11.8 Accrued Obligations. Except where expressly provided for otherwise in
this Agreement, termination of this Agreement shall not relieve the Parties
hereto of any liability, including without limitation, any obligation to make
payments hereunder, which accrued hereunder prior to the effective date of such
termination, nor preclude any Party from pursuing all rights and remedies it may
have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice any Party's right to obtain performance of any
obligation. Upon termination, expiration or cancellation of this Agreement for
any reason and subject to Sections 5.3(b), 11.4(a), 11.4(b) 11.4(e), Fujisawa
shall not be required to make any milestone payments or royalty payments that
may be due from and after the effective date of termination. The Parties further
acknowledge and agree that notwithstanding anything to the contrary contained in
this Agreement, any DTI patent infringement action brought by Fujisawa under
Section 9.2 which is ongoing as of the time of such termination or expiration
shall be transferred to DTI, upon DTI's request. In such event, Fujisawa shall
have no responsibility with respect to the prosecution of any such action
pertaining to the infringement of the DTI Patents.

     11.9 Surviving Obligations. Surviving any termination are:

          (a)  any cause of action or claim of Fujisawa or DTI, accrued or to
accrue, because of any breach or default by the other Party;

          (b)  the provisions of Sections 3.9 (with respect to DTI's rights and
subject to Section 5.5), 4.4, 5.5, 5.6, 5.12, 7.1, 7.2, 7.3, 8, 9.1, 9.5, 10, 11
and 14; and

          (c)  any accrued obligations under Section 11.8.

12.  ASSIGNMENT

     12.1 This Agreement and the rights, duties and obligations hereunder may
not be assigned by either Party without the prior written consent of the other
Party except to an Affiliate or in connection with a merger, consolidation or
sale of all or substantially all of the assets or line of business of such Party
to which this Agreement relates. This Agreement shall be binding upon and inure
to the benefit of all successors and permitted assigns of the Parties.

13.  DISPUTE RESOLUTION

     13.1 Discussion. In the event of any dispute between the Parties regarding
their respective rights or obligations under this Agreement, each Party agrees
to discuss such matter in good faith in an effort to resolve the dispute without
resort to formal dispute resolution procedures. At any time, either Party may
call a meeting between a member of Fujisawa's Executive Committee and the Chief
Executive Officer of DTI to attempt to resolve the dispute. Such meeting shall
be held not later than ten (10) days after it is requested in writing by either

                                       33

<PAGE>

Party in New York, New York. If such dispute cannot be resolved through such
procedures within fifteen (15) days of the date either Party requests a meeting
of the officers designated above, then either Party may request an arbitration
proceeding as provided in Section 13.2.

     13.2 Alternative Dispute Resolution. Any dispute, controversy or claim
arising out of or relating to the validity, construction, enforceability or
performance of this Agreement, including disputes relating to an alleged breach
or to termination of this Agreement and including any claim of inducement by
fraud or otherwise, but excluding (i) any dispute, regarding the validity,
enforceability, or infringement of any DTI Patent or trademark applicable to a
Licensed Product and (ii) any dispute which is expressly prohibited herein from
being resolved by this mechanism, shall be settled by binding Alternative
Dispute Resolution ("ADR") by Mediation and Arbitration in the manner described
below:

     13.3 Mediation.

          (a)  Any such dispute, controversy or claim which would, but for this
provision, be submitted to arbitration may upon the mutual written agreement of
the Parties, before submission to arbitration, first be mediated through
non-binding mediation in accordance with the Model Procedures for the Mediation
of Business Disputes promulgated by the Center for Public Resources ("CPR") then
in effect, except where those rules conflict with these provisions, in which
case these provisions control. The mediation shall be conducted in the United
States and shall be attended by a senior executive with authority to resolve the
dispute from each of the operating companies that are Parties.

          (b)  Subject to Section 3.5(c), the mediator shall be appointed from
the list of neutrals maintained by CPR.

          (c)  The Parties shall promptly confer in an effort to select a
mediator by mutual agreement. In the absence of such an agreement, the mediator
shall be selected from a list generated by CPR with each Party having the right
to exercise challenges for cause and two peremptory challenges within 72 hours
of receiving the CPR list, subject to Section 3.5(c).

          (d)  The mediator shall confer with the Parties to design procedures
to conclude the mediation within no more than 30 days after initiation. Under no
circumstances shall the commencement of arbitration under Section 13.4 be
delayed more than 45 days by the mediation process specified herein.

          (e)  Each Party agrees to toll all applicable statutes of limitation
during the mediation process and not to use the period or pendancy of the
mediation to disadvantage the other Party procedurally or otherwise. No
statements made by either side during the mediation may be used by the other
during any subsequent arbitration.

          (f)  Each Party has the right to pursue provisional relief from any
court, such as attachment, preliminary injunction, replevin, etc., to avoid
irreparable harm, maintain the status quo, aid the arbitration or preserve the
subject matter of the arbitration, even though mediation has not been commenced
or completed.

                                       34

<PAGE>

     13.4 Arbitration. Except as provided in paragraph (c) below and subject to
Section 3.5(c), any dispute, controversy or claim arising out of or relating to
the validity, construction, enforceability or performance of this Agreement
which is not resolved by mediation, including disputes relating to alleged
breach or to termination of this Agreement, other than disputes which are
expressly prohibited under Section 13.2 from being resolved by this mechanism,
shall be settled by binding Alternative Dispute Resolution ("ADR") in the manner
described below:

          (a)  If a Party intends to begin an ADR to resolve a dispute, such
Party shall provide written notice (the "ADR Request") to counsel for the other
Party informing such other Party of such intention and the issues to be
resolved. From the date of the ADR Request and until such time as any matter has
been finally settled by ADR, the running of the time periods contained in
Section 11.2 as to which Party must cure a breach of this Agreement shall be
suspended as to the subject matter of the dispute.

          (b)  Within ten (10) business days after the receipt of the ADR
Request, the other Party may, by written notice to the counsel for the Party
initiating ADR, add additional issues to be resolved.

          (c)  Notwithstanding anything to the contrary contained herein, any
dispute regarding the validity, enforceability, or infringement of any DTI
Patent or trademark applicable to a Licensed Product shall be submitted to a
court of competent jurisdiction in the country in which such patent or trademark
right exists.

     13.5 Procedure. The ADR shall be conducted pursuant to JAMS/ENDISPUTE
Streamlined Arbitration Rules & Procedures or Comprehensive Arbitration Rules
and Procedures (collectively, the "Rules"). Notwithstanding those rules, the
following provisions shall apply to the ADR hereunder.

          (a)  Arbitrator. The arbitration shall be conducted by a single
arbitrator knowledgeable about drug development ("the Arbitrator"). The
Arbitrator shall be selected from a pool of retired independent federal judges
to be presented to the Parties by JAMS/ENDISPUTE. Neither Party shall engage in
ex parte contact with the arbitrator without first giving reasonable advance
written notice to the other Party and an opportunity to participate in such
contact.

          (b)  Proceedings. The time periods set forth in the JAMS/ENDISPUTE
rules shall be followed, unless a Party can demonstrate to the Arbitrator that
the complexity of the issues or other reasons warrant the extension or
shortening of one or more of the time tables. In such case, the panel may extend
or shorten such time tables, but in no event shall the time tables being
extended so that the ADR proceeding extends more than 12 months from its
beginning to the Award. In regard to such time tables, that Parties (i)
acknowledge that the issues that may arise in any dispute involving this
Agreement may involve a number of complex matters and (ii) confirm their
intention that each Party will have the opportunity to conduct reasonable
discovery with respect to all material issues involved in a dispute within the
framework provided above. The Parties will exchange information as required
under current Rule 15 of the JAMS/ENDISPUTE Comprehensive Arbitration Rules and
Procedures except that (i) in addition to exchanging the names of all experts
who may be called to testify or whose report may be

                                       35

<PAGE>

introduced at the ADR hearing, the Parties shall also provide, simultaneously
with the names of all such experts, a copy of any report(s) (including all
backup) prepared by the experts, and (ii) notwithstanding anything in Rule 15 to
the contrary, and unless the Parties otherwise agree or the Arbitrator decides
upon application of a Party that additional depositions are warranted, each
Party shall be entitled to conduct one deposition of each of the opposing
Party's experts and, in addition, shall be entitled to conduct two depositions
of the opposing Party or of individuals under the control of the opposing Party.
The Arbitrator shall not award punitive damages to either Party and the Parties
shall be deemed to have waived any right to such damages. The Arbitrator shall,
in rendering its decision, apply the substantive law of the State of Delaware,
without regard to its conflict of laws provisions, except that the
interpretation of and enforcement of this Section shall be governed by the
Federal Arbitration Act. The Arbitrator shall apply the Federal Rules of
Evidence to the hearing. The proceeding shall take place in the United States.
The fees of the Arbitrators and JAMS/ENDISPUTE shall be paid by the losing
Party, which shall be designated by the Arbitrator. If the Arbitrator is unable
to designate a losing Party, it shall so state and the fees shall be split
equally between the Parties.

                (c)     Award. The Arbitrator is empowered to award any remedy
allowed by law, including money damages, prejudgment interest and attorneys'
fee, and to grant final, complete, interim, or interlocutory relief, including
injunctive relief but excluding punitive damages.

                (d)     Confidentiality.  The ADR proceeding shall be
confidential and the Panel shall issue appropriate protective orders to
safeguard each Party's confidential Information. Except as required by law, no
Party shall make (or instruct the Panel to make) any public announcement with
respect to the proceedings or decision of the Panel without prior written
consent of each other Party. The existence of any dispute submitted to ADR, and
the award, shall be kept in confidence by the Parties and the Panel, except as
required in connection with the enforcement of such award or as otherwise
required by applicable law or upon the written request to the Arbitrator with
notice to the other Party.

14.     GENERAL

        14.1    Notices. All notices under this Agreement shall be deemed to
have been fully given when done in writing and faxed to the other Party,
deposited in the United States mail, registered or certified, or sent by express
courier (receipt confirmed) and addressed as follows:

                To DTI:                 2028 Dabney Road, Suite E-17
                                        Richmond, VA 23230-3311
                                        Fax No.:   (804) 358-2451
                                        Attention: Chief Executive Officer

                With a copy to:         Cooley Godward LLP
                                        5 Palo Alto Square
                                        3000 El Camino Real
                                        Palo Alto, CA 94306
                                        Fax No.:   (650) 857-0663
                                        Attention: Barbara A. Kosacz, Esq.

                                       36

<PAGE>

                To Fujisawa:            Fujisawa Healthcare, Inc.
                                        Parkway North Center
                                        Three Parkway North
                                        Deerfield, ILL 60015-2548
                                        Fax No.:   (847) 317-7288
                                        Attention: Chief Executive Officer

                With a copy to:         General Counsel

Either Party may change its address upon written notice to the other Party.

        14.2    Retained Rights. Subject to Sections 2.5 and 3.8, nothing in
this Agreement shall limit in any respect the right of either Party to conduct
research and development and to market products using such Party's technology
other than as herein expressly provided. Furthermore, nothing in this Agreement
shall be construed to provide any license, implied or express, under any patent
controlled by a Party, except to the extent expressly granted with respect to
Licensed Products that are the subject of continuing development and
commercialization pursuant to this Agreement.

        14.3    Consents Not Unreasonably Withheld or Delayed.  Whenever
provision is made in this Agreement for either Party to secure the consent or
approval of the other, that consent or approval shall not unreasonably be
withheld or delayed, and whenever in this Agreement provision is made for one
Party to object to or disapprove a matter, such objection or disapproval shall
not unreasonably be exercised, even when not so expressly stated.

        14.4    Force Majeure. Neither Party shall lose any rights hereunder or
be liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, embargo, act of God,
failure to supply by Third Party contract manufacturer or any other similar
cause beyond the control of the defaulting Party, provided that the Party
claiming force majeure has exerted all reasonable efforts to avoid or remedy
such force majeure and has given the other Party prompt notice describing such
event, the effect thereof and the actions being taken to avoid or remedy such
force majeure; provided, however, that in no event shall a Party be required to
settle any labor dispute or disturbance.

        14.5    Further Actions.  Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

        14.6    No Trademark Rights. Except as otherwise provided herein, no
right, express or implied, is granted by the Agreement to use in any manner any
name or any trade name or trademark of the other Party in connection with the
performance of this Agreement.

        14.7    Waiver. Except as specifically provided for herein, the waiver
from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of same or any other of such Party's rights or remedies provided in this
Agreement.

                                       37

<PAGE>

        14.8    Independent Contractors. The status of the Parties under this
Agreement shall be that of independent contractors. Neither Party shall have the
right to enter into any agreements on behalf of the other Party, nor shall it
represent to any person that it has any such right or authority. Nothing in this
Agreement shall be construed as establishing a partnership, agency or joint
venture relationship between the Parties.

        14.9    Entire Agreement. This Agreement and the Exhibits attached
hereto embodies the entire understanding between the Parties relating to the
subject matter hereof and supersedes all prior understandings and agreements,
whether written or oral. None of the terms of this Agreement can be amended or
waived except by an instrument in writing executed by authorized representatives
of each Party.

        14.10   Governing Law.  This Agreement shall be governed by the laws of
the State of Delaware, without regard to conflict of laws principles.

        14.11   Severability. Any of the provisions of this Agreement which are
determined to be invalid or unenforceable in any jurisdiction shall be
ineffective to the extent of such invalidity or unenforceability in such
jurisdiction, without rendering invalid or unenforceable the remaining
provisions hereof or affecting the validity or enforceability of any of the
terms of this Agreement in any other jurisdiction.

        14.12   Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which taken
together shall constitute one and the same instrument.

        IN WITNESS WHEREOF, the Parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

Discovery Therapeutics, Inc.                    Fujisawa Healthcare, Inc.

By:    /s/ Donald A. McAfee                     By:    /s/ Noboru Maeda
       -------------------------------------           -------------------------
Name:  Donald A. McAfee                         Name:  Noboru Maeda
Title: President and Chief Executive Officer    Title: Chief Executive Officer

                                       38

<PAGE>

                                    EXHIBIT A

                                    COMPOUND*

--------------------------------------------------------------------------------

 *  Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.

--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT B

                                DEVELOPMENT PLAN

                                       *

--------------------------------------------------------------------------------

Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT C

                              DEVELOPMENT EXPENSES

SUMMARY OF DTI EXPENDITURES JANUARY - JULY, 1999

       Drug Substance Manufacturing (*)                                *

       Drug Substance Characterization (*)                             *

       Drug Product Manufacturing (PDC)                                *

       Regulatory (Quintiles)                                          *

       Plasma Assay (PPD)                                              *

       Toxicology (Covance)                                            *

       DTI Internal Effort 1Q99                                        *

       DTI Internal Effort 2Q99                                        *

       DTI Internal Effort July                                        *

       Grand Total Expenditures Due in accordance with Section 5.2
       of the Development and License Agreement                        *

--------------------------------------------------------------------------------

 *  Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.

--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT D

                             [Intentionally omitted]

<PAGE>

                                    EXHIBIT E

                              PHASE I TRIAL BUDGET

<TABLE>
<CAPTION>
        Activity                           Vendor       Cost
-------------------------              ------------- ----------
<S>                                    <C>           <C>
Clinical Site Expenses                        *           *
Data Management                               *           *
Randomization                                 *           *
Medical Monitor                               *           *
Plasma Assay                                  *           *
Bulk Drug Stability                           *           *
Drug Product Stability                        *           *
Drug Product Storage                          *           *
Regulatory                                    *           *
DTI Internal FTE and Misc.                                *
DTI Travel to Clinical Site                   *           *

Total                                                     *

Estimated Amount due from Fujisawa per
Section 5.2 of Development and License
Agreement                                                 *

Assumptions:
% of total supporting Licensed Products
studies                                       *
</TABLE>

--------------------------------------------------------------------------------

 *  Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT F

U.S. PATENT NO:                      5,310,731
                                     Issued May 10, 1994

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]